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Abstract
Part I
Objective: To conﬁrm ﬁndings of a previous, unpublished work which are:
(1) to provide empirical estimates of the correlation coeﬃcient between base-
line measurement and ﬁnal outcome in the context of the analysis of change
and (2) explore over-time and between-treatment arms homoscedasticity as-
sumptions.
Study Design and Setting: A literature search of parallel clinical tri-
als published in the years 2010 and 2013 which provided baseline and at
least ﬁnal or diﬀerence variability for a quantitative endpoint was performed.
Outcome-baseline correlation was calculated from variability measures and
treatment eﬀect uncertainty estimates. Subgroup analyses were performed
according to publication year, analysis type, reported information and kind
of measure. Homoscedasticity assumptions were explored by the ratio of the
standard deviation estimates and the Lin concordance correlation coeﬃcient.
Results: Of 164 selected papers, 96 provide consistent information to es-
timate the correlation coeﬃcient. Mean was 0.758, with 95% conﬁdence
interval from 0.668 to 0.826. Among these papers, 33 (34.4%) have an esti-
mated correlation lower than 0.5, including 5 (5.2%) with negative values of
which 4 have a subjective outcome. In the subgroup analyses, statistically
signiﬁcant diﬀerences were revealed only in the kind of outcome. The results
are in accordance with the homoscedasticity assumptions.
Conclusions: This study advises that trialists should avoid trusting pub-
lished reliability values when determining sample size and be prepared for
low correlation values. Additional implications may be: (1) reporting of
variability values should be improved; (2) assumptions of homoscedasticity
hold true in general; and (3) baseline restriction further improves ANCOVA
eﬃciency.
Part II
Objective: To evaluate the performance of statistical methods that are
commonly applied to longitudinal data in randomized clinical trials (RCTs)
with repeated measurements and a quantitative outcome with a simulation
study.
i
Study Design and Setting: A systematic literature review of RCTs with
parallel groups, quantitative primary outcome and repeated measurements
published in 2014 was conducted in order to guide the simulation parameters.
Based on this, data with varying sample sizes, eﬀect sizes, residual variances,
random slope variances and correlation structures was simulated. On this
simulated data, we compared the performance of: a summary statistic, re-
peated measures analysis of variance (rmANOVA) and several generalized
estimating equations (GEEs) and linear mixed models (LMMs) with diﬀer-
ent assumptions. Primary performance measure is Power and Type I Error
and secondary performance measures are Mean Square Error and coverage
of the 95% conﬁdence interval.
Results: Summary statistics and rmANOVA perform poorly compared to
GEEs and LMMs. If the within-subject measures are uncorrelated or follow
an exchangeable correlation structure, GEEs perform best. In case of an
auto-regressive correlation structure or an unstructured dependency, LMMs
perform better than GEEs.
Conclusions: This study advises that trialists should not use summary
statistics or rmANOVA to analyse data of RCTs with repeated measures. In
the unlikely event of no correlation between the within-subject measures or
compound symmetry, GEEs are the best choice. Unstructured dependency
or an auto-regressive correlation structure are more likely to occur in real
RCTs with repeated measures. In these cases, LMMs should be used.
ii
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1. Introduction
This master thesis is split into two separate main parts. Part I is a meta-analysis of
randomized clinical trials (RCTs) and Part II is a simulation study.
First, a meta-analysis was performed through a literature search of RCTs of the years
2010 and 2013. The goal was to conﬁrm results of a preliminary work which analysed
RCTs from the years 2004 and 2007. These include empirical estimates of the correlation
coeﬃcient between baseline and ﬁnal measurement and assumptions on homoscedastic-
ity between (1) ﬁnal and baseline standard deviation and (2) ﬁnal standard deviation of
treatment and control group.
Second, diﬀerent data sets of RCTs with repeated measurements and a continuous out-
come were simulated with varying sample sizes, eﬀect sizes, residual variances, random
slope variances and correlation structures. The goal was to compare statistical methods
that can be applied to longitudinal data. Primary performance measure is Power and
Type I Error and secondary performance measures are coverage of the 95% conﬁdence
interval around the true eﬀect and Mean Square Error. The applied methods are a
summary statistics [1], repeated measures analysis of variance (rmANOVA) [2], linear
mixed models (LMMs) [3] and generalized estimating equations (GEEs) [4].
Both parts of this thesis include a separate introduction in chapter 2.1 and 3.1. Chapter
2.2 describes the systematic literature review for the meta-analysis and the analysis of
the data which is collected from the papers. After that, the results are presented in
chapter 2.3 followed by a discussion of these results in chapter 2.4. After the introduc-
tion of the second part of this thesis, the literature review for the determination of the
simulation parameters and the performance measures are described in chapter 3.2. In
chapter 3.3, the statistical methods that are applied on the simulated data are outlined.
This is followed by the the presentation of the results in chapter 3.4 and a discussion in
chapter 3.5.
2. Part I
2.1. Introduction
In a randomized clinical trial with a quantitative endpoint Y , the main reason for adjust-
ment is to improve eﬃciency through the reduction of residual variance. The baseline
measurement Z of Y is a popular adjustment variable maybe because it is expected
to account for a large proportion of the Y variance. When designing a conﬁrmatory
pivotal trial, the beneﬁt in the reduction of sample size may be deduced from the results
of previous exploratory trials or from similar available studies. Otherwise, information
comes generally from reliability studies which require patient stability.
Let Zij and Yij be the baseline and outcome value for patient j, j = 1, ..., ni and treat-
ment i, i = 0, 1. We can arbitrarily designate the value 0 for the index i as being control
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and the value 1 as being experimental. We assume the following model.
Zij = µZ + αij + ij1 (1)
Yij = µY + τi + αij + ij2 (2)
αij ∼ N(0, σ2α) (3)
ijk ∼ N(0, σ2k), k = 1, 2 (4)
Where αij represents the patient idiosyncrasy (among patient diﬀerences that remain
constant during the two measured periods), which we model with a normal distribution
with variance σ2α and the within patient error ijk, where k = 1 stands for baseline and
k = 2 for post-baseline measurement. The treatment eﬀect is represented by τ1 − τ0.
This diﬀerence is identiﬁable, although the individual terms are not. The secular change,
that is to say the diﬀerence that would be observed over time in the absence of any
treatment eﬀect, is represented by µY − µZ . This particular formulation represents the
pure between-patient eﬀect as being stable but allows any change in variance over time
to be reﬂected through the diﬀerence between σ21 and σ
2
2
. Although this model allows
for the variance to diﬀer between baseline and outcome, it assumes homoscedasticity
across treatments.
If we assume that the three random terms αij, ij1 and ij2 are independent then the
correlation coeﬃcient ρ can be calculated by (5).
ρ =
σ2ZY√
σ2Z
√
σ2Y
=
σ2α√
(σ2α + σ
2
1
)
√
(σ2α + σ
2
2
)
(5)
If we make the further assumption that σ21 = σ
2
2
= σ2 , that is homoscedasticity between
baseline and ﬁnal measurement, then
ρ =
σ2α
σ2α + σ
2

(6)
and so, the correlation coeﬃcient represents the proportion of variance among individuals
over the total variance. If we further assume that the patient status does not change,
that is, that ijk is only the result of the measurement error, the correlation coeﬃcient ρ
corresponds to the reliability coeﬃcient [5]. Note that this model implies that ρ should
be positive.
The change or outcome−baseline diﬀerence is deﬁned as Dij = Yij−Zij and its variance
is
V ar(Dij) = V ar(Yij − Zij) = σ21 + σ22 (7)
The treatment eﬀect is usually estimated by one of three methods jointly modeled as
τ(b) = (Y¯1−Y¯0)−b(Z¯1−Z¯0) [6]. Depending upon the value of b, we obtain either the ﬁnal
estimator τˆ(0), the change score τˆ(1) or the analysis of covariance (ANCOVA) τˆ(β). In
a randomized clinical trial with identical follow up and complete outcome determination,
all three estimators are unbiased and their respective variances are represented in table
1.
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Estimator Variance
τˆ(0): Final outcome qσ2Y
τˆ(1): Change from baseline q(σ2Y + σ
2
Z − 2ρσY σZ)
τˆ(β): ANCOVA q(1− ρ2)σ2Y
Table 1: Variance of Senn's estimators. q = 1/n0 + 1/n1; ρ: correlation between ﬁnal
and baseline measurements.
This implies that τˆ(β) is the most eﬃcient estimator for any value of ρ and that τˆ(1)
is more eﬃcient than τˆ(0) for ρ > 0.5, but less eﬃcient in the opposite situation [7].
However, this threshold is only true in the case that basal and ﬁnal variances are the
same as shown in ﬁgure 1. Here, variances of the three treatment eﬀect estimators
as a function of the correlation ρ and the ﬁnal−baseline ratio θ = σY
σZ
are displayed.
θˆ(β) is the most eﬃcient in all cases. θˆ(0) and θˆ(β) depend only on ρ, but θˆ(1) is
more eﬃcient than θˆ(0) if ρ > 0.5θ−1. The greater σY , the greater must be ρ in order
that θˆ(1) be more eﬃcient than θˆ(0). Variance of θˆ(1) is shown for the ﬁve scenarios
θ = 2/3, 4/5, 1, 5/4, 3/2. Without loss of generality, the variance of θˆ(0) has been ﬁxed
to qσY = 1, for illustration purposes.
Figure 1: Variances of the three treatment eﬀect estimators as a function of the correla-
tion value (ρ) and the ﬁnal/baseline SD ratio (θ = σY /σZ) [8]
In addition, a slight caveat must be entered here: the formula for the ANCOVA variance,
unlike for the other two, is strictly correct only if the slope β = ρσY
σZ
is known. As it is
usually estimated from the same data, one degree of freedom is lost, which implies some
variance inﬂation [6, 9]. However, it is negligible for moderately sized or larger samples.
Similarly to Garcia et al [10], who empirically estimated the correlation coeﬃcient ρ in
cross-over studies, our objective has been to provide empirical estimates of ρ through
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a literature search of published studies from the years 2010 and 2013 and to study the
relationship with the relative eﬃciency of the three mentioned estimators. A secondary
objective has been to check if the assumptions about homoscedasticity, both between
treatment groups and over time, are met. A previous, unpublished work already analysed
published studies from the years 2004 and 2007. Reasons for the new analysis are to
conﬁrm previous ﬁndings and expand the view of evolution.
2.2. Methods
2.2.1. Bibliographical search
Articles from the years 2010 and 2013 were selected from Medline in the intranet at
Barcelona Tech on January 23, 2015 with the following search criteria.
AB((trial* AND random*) AND
((change OR evolution) AND (diﬀerence AND baseline))) (8)
AB() means that the keywords have to appear in the abstract and * searches for vari-
ations on a word that are formed with diﬀerent suﬃxes. For example, random* ﬁnds
occurrences of random, randomly, randomised and randomized.
While looking for the optimal search strategy for the meta-analysis diﬀerent approaches
were considered. Without the demand of the keywords appearing in the abstract, more
than 1000 papers per year were found. Also, previous strategies included clinical trial*
instead of trial* only, what boldly decreased the amount of papers found.
Our target population was randomized clinical trials with parallel groups reporting re-
sults of the primary, quantitative outcome of the trial. Papers which do not report
baseline and diﬀerence variability data have to be excluded from the primary analysis
because of the impossibility of estimating the correlation coeﬃcient.
To determine if a paper was a randomized clinical trial with parallel groups and a quan-
titative primary outcome the abstracts of all identiﬁed papers were read. For a decent
amount of papers a closer look at the whole work was necessary to determine the primary
outcome of the trial. A strategy to determine the primary outcome in case it was not
explicitly stated is described in section 2.2.2. After the papers belonging to the target
population were identiﬁed, those were read completely to collect the variables presented
in section 2.2.2.
2.2.2. Collected Variables
For studies with more than one or unspeciﬁed primary outcome or more than two treat-
ment arms, selected outcome and selected treated group were determined with the fol-
lowing hierarchical criteria: (1) objective or hypothesis of the trial; (2) sample size
determination; (3) main statistical method for analysis; or (4) ﬁrst reported in results.
Collected variables were: baseline, outcome and diﬀerence standard deviation; primary
outcome; type of treatments; kind of outcome (automatic device or subjective evalua-
tion); sample size; statistical analysis method and journal.
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2.2.3. Correlation estimation
For the papers with available baseline, ﬁnal and change variability, the correlation co-
eﬃcient was estimated by (9) with baseline variance σˆ2Z , ﬁnal variance σˆ
2
Y and change
variance σˆ2D.
ρˆ =
σˆ2ZY√
σˆ2Z σˆ
2
Y
=
σˆ2Z + σˆ
2
Y − σˆ2D
2
√
σˆ2Z σˆ
2
Y
(9)
If the ﬁnal variance was not reported, the intra-subject variance σ2 was estimated from
the variance of change σ2D by
σ2D = 2σ
2
 ⇒ σˆ2 =
σˆ2D
2
. (10)
Assuming that σˆ21 = σˆ
2
2 = σˆ
2
 and independence among αij and both ij1 and ij2, the
between-subject variance σ2α (11) and the correlation coeﬃcient ρ (12) were estimated.
σˆ2α = σˆ
2
Y − σˆ2 (11)
ρˆ =
σˆ2α
σˆ2α + σˆ
2

=
σˆ2Y − σˆ
2
D
2
σˆ2Y
(12)
Finally, the baseline variance was employed to estimate overall outcome variance σ2,
making the homoscedasticity assumption σ2Z = σ
2
Y = σ
2. In order to estimate a conﬁ-
dence interval for ρ and to compare correlation coeﬃcients among subgroups, Fisher's
transformation [11] was used.
2.2.4. Homoscedasticity assumptions
The over−time and between−treatment arms homoscedasticity assumptions were ex-
plored by the ratio of their respective standard deviation estimates and the Lin concor-
dance correlation coeﬃcient [12] which was calculated for the log-transformed standard
deviations. For the former, all studies reporting baseline and ﬁnal variance were selected
(irrespective of the reporting of the diﬀerence variance) and for the latter, only stud-
ies with a passive control group (either placebo or no active treatment) reporting ﬁnal
variability.
2.3. Results
2.3.1. Flow of papers
Figure 2 shows selection criteria and paper ﬂow. We retrieved 478 papers in 2010 and
657 papers in 2013. In order to reduce the amount of work a sample of 300 papers for
each year was drawn by means of the sample function in R [13] with a seed of 123456
which was chosen before looking at the papers in order to avoid the risk of bias due to
selective outcome reporting.
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Figure 2: Papers ﬂow diagram
Our target population consists of 170 of 300 papers in the year 2010 and 165 of 300
papers in 2013. From these, 98 did not provide enough data to be included in the analysis
because they did not report ﬁnal and change variability or the data was only reported as
median and interquartile range, least square means or percent change. Furthermore the
full text version of 72 papers was not available. There was one exclusion [14] because
the estimate from this paper has an absolute value greater than one, which has no
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sense. This leaves 164 papers reporting variability data and 96 papers that provide
enough information to estimate the correlation ρ. The references of the papers reporting
variability are listed in appendix A.1 and A.2.
2.3.2. Correlation coeﬃcient estimation
−0.5
0.0
0.5
1.0
baseline, change baseline, outcome, change
Reported data
Co
rre
la
tio
n 
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ef
fic
ie
nt
Figure 3: Shape of the estimated ρ coeﬃent depending on whether or not outcome vari-
ance is reported
A total of 96 papers, which reported the change score variance, allowed the estimation of
the correlation ρ. All of them provided the baseline variance, however, only 56 (58.3%)
provided the ﬁnal variance also. There are 33 (34.4%) correlations less than 0.5 of which
5 (5.2%) are negative. The authors of the corresponding papers were contacted by mail
and three of them conﬁrmed the data as reported whereas two did not answer. Table
2 contains some descriptive statistics and ﬁgure 3 shows the distribution shape for the
estimations.
The estimate for the correlation mean after the Fisher transformation was 0.758, (95%-
CI: 0.668 to 0.826). Correlation was very similar when baseline variance was employed
instead of outcome variance (in the case that outcome variance was not reported). The
diﬀerence between the two subgroups (baseline, outcome and change reported vs baseline
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and change reported) after Fisher transformation was 0.061 (95%-CI: −0.115 to 0.203),
whereas the mean for the group that did not report outcome variability was greater.
N Minimum Q1 Median Q3 Maximum Mean SD
All 96 -0.659 0.430 0.652 0.844 1.000 0.608 0.308
BOC 56 -0.100 0.437 0.649 0.816 0.999 0.626 0.238
BC 40 -0.659 0.414 0.685 0.873 1.000 0.584 0.386
Table 2: Descriptive statistics for the estimated ρ coeﬃcient (without any transforma-
tion). BOC: Papers that reported baseline, outcome and change variability.
BC: Papers that reported only baseline and change variability
Because change variance was more than double the baseline, we obtained negative cor-
relation values in 5 studies with baseline values restricted by eligibility criteria [15, 16,
17, 18, 19] of which 4 had subjective outcomes that needed personal interpretation.
In the subgroup analyses, only the outcome type showed statistically signiﬁcant diﬀer-
ences. Correlations for automatic outcomes were 0.292 (95%-CI: 0.142 to 0.454) higher
than those needing a personal interpretation. For example, the paper from Smith et al.
[20] had a subjective outcome such as the Montgomery-Asberg Depression Rating Score
(MADRS) with a low correlation of 0.270, while the paper from Samuel-Hodge et al.
[21] had an automatic response such as weight in kilograms and a very high correlation
of 0.942. No signiﬁcant eﬀects were found for publication year (2010 versus 2013; dif-
ference: 0.021; 95%-CI: −0.133 to 0.198), amount of variability data reported (baseline
and change versus baseline, outcome and change; 0.061; −0.115 to 0.203) and method
of statistical analysis (ANCOVA, ANOVA, t-test or other; p = 0.203).
2.3.3. Homoscedasticity assumption
N Minimum Q1 Median Q3 Maximum Mean
Baseline-Final 124 0.200 0.924 1.025 1.143 2.976 1.113
Treated-Control 55 0.202 0.870 0.977 1.138 4.946 1.057
Table 3: Descriptive statistics for the ratio of ﬁnal-initial SD values (ﬁrst row) and for
the outcome treated-control arms SD ratio (second row)
Descriptive statistics of the ratio between the baseline and the outcome standard devi-
ation for the 124 papers (table 3 and ﬁgure 4) are in accordance with the initial-ﬁnal
homoscedasticity assumption. The Lin coeﬃcient of concordance was 0.973 (95%-CI:
0.962 to 0.981). Variability of treated and control groups were retrieved from 55 papers.
Again, both are in accordance with the between-group homoscedasticity assumption.
The Lin coeﬃcient of concordance was 0.965 (95%-CI: 0.942 to 0.980).
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Figure 4: Bland-Altman plot for the diﬀerence versus the average of outcome logarithms
and baseline SD (left) and for the diﬀerence versus the average of treated
versus control outcome SD (right)
2.4. Discussion
2.4.1. Correlation coeﬃcient estimation
One study [15] (1.0% of the 98 that reported suﬃcient variability) was excluded because
of an incoherent correlation value (i.e., lower than −1 or greater than 1), a lower pro-
portion than those found for the studies from the years 2004 and 2007 (4.4% of 68) and
by the Agency for Healthcare Research and Quality (AHRQ) (5.0%) [22]. García et al
[10] reported the correlation coeﬃcient between the two periods of 22 cross-over studies
with a median of 0.651 and a proportion of 22.7% (5/22) trials below 0.5, quite similar
to our results of 0.652 and 34.4% and the results of 0.689 and 29.2% from the years
2004 and 2007. Correlation coeﬃcients below 0.5 imply that the beneﬁt of accounting
for baseline values by simple subtraction will be negative, τˆ(1), or fairly small, τˆ(β). In
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those situations, instead of accounting for the between-patient variance, greater beneﬁt
could be achieved by controlling the within-patient variance, for example, by averaging
repeated outcome measurements [23]. Although greater eﬃciency is generally obtained
by adjusting baseline values, Austin et al [24] showed that an adjusted treatment eﬀect
is reported in only 34.2% of the trials.
It is worth highlighting that correlation coeﬃcients were higher for automatically de-
termined outcomes, suggesting that clinical trial researchers might choose, if relevant,
one of those variables in order to beneﬁt the greater eﬃciency provided by τˆ(1) and
especially by τˆ(β) estimators.
2.4.2. Negative correlations
When adjusting by baseline values, researchers expect the beneﬁts of a positive corre-
lation with outcome. However two studies in 2004 and 2007 and 5 studies in 2010 and
2013 with negative values were recovered. Such negative values imply that a ﬁnal pa-
tient value would more closely resemble the initial values of other patients rather than
their own. Some explanations could include: heteroscedasticity, low reliability, baseline
variance restriction (by selecting highly homogeneous patients), instability in patient
condition due to the treatment and low arithmetic precision when reporting dispersion
values. Furthermore, only 1 of the 7 papers had an automatic outcome: HbA1C [15].
The others had subjective outcomes: HAMA, MADRS, pain assessment score (faces
scale or VAS depending on age of children), prednisolone dose which was changed de-
pending on the BILAG score and if the patient ﬂared, pain intensity (11-point numerical
rating scale) and T4SS [16, 17, 18, 19, 25, 26]. The psychometric scales HAMA and
MADRS have very high test-retest reliability: 0.86 and 0.98, respectively [27, 28].
Furthermore, as reliability may vary according to the lapse in time, the measurement
process should be speciﬁed [29]. Moreover, a straightforward explanation of this nega-
tive correlation is a cyclical variation of disease status  a well-known, usual situation
in some psychological conditions such as depression in bipolar patients. This negative
correlation induces a loss of power for the `change from baseline' but, interestingly, it
still provides beneﬁts for the ANCOVA analysis.
2.4.3. Homoscedasticity
One useful assumption for future interventions is that the treatment eﬀect size is just
a constant τ without any random component. This is a strong assumption that, if
needed, can be relaxed by adding a random treatment eﬀect within the more general
framework of longitudinal mixed models [30]. But, on average, our data fulﬁlled the two
homoscedasticity assumptions: diﬀerences were found neither (1) between the ﬁnal and
the baseline SD, nor (2) between the ﬁnal values of the treated and the control group.
Very similar results were found for the years 2004 and 2007. However, we observed large
extreme values both for the initial-ﬁnal outcome SD ratio (0.200 and 2.976) and for the
SD ratio between the treated and the control group (0.202 and 4.946). Although those
extreme values can be the result of sampling variation, researchers should still carefully
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consider these assumptions in their speciﬁc situations.
In the introduction, it was stated that τˆ(1) is more eﬃcient than τˆ(0) as long as the
correlation ρ is over 0.5, assuming σY = σZ . However, in the more general case, being
that σY = θσZ , the previous condition ρ > 0.5 now becomes ρ > 0.5θ
−1. Then, for
θ 6= 1, τˆ(1) is better if ρθ = ρσY
σZ
> 0.5. As an example, in the extreme case of the study
from Buckley et al. [31], SY
SZ
≈ 3, the correlation should be greater than 1
6
for τˆ(1) to be
more eﬃcient (see ﬁgure 1).
2.4.4. Eﬃciency under baseline restriction
Some researchers may design the trial by implicitly adjusting twice, using baseline val-
ues: (1) restricting baseline variance using the eligibility criteria; and (2) accounting
again for baseline heterogeneity in the statistical analysis  either with τˆ(1) or τˆ(β).
The behavior of the two less eﬃcient estimators becomes closer to the ANCOVA as the
baseline restriction increases. But then initial-outcome homoscedasticity no longer holds
and, as we have seen, the beneﬁt of the analysis of change requires higher correlations.
Interestingly, the eﬃciency of the more powerful strategy  the ANCOVA  seems to
be further improved by baseline restriction for ρ > 0.2. If so, baseline determination
may improve eﬃciency in two ways: (1) reducing patient variability by baseline restric-
tion; and (2) accounting for it in the analysis. In the ﬁnal balance, it should be noted,
however, that restricting the population makes recruitment more diﬃcult and may com-
promise external validity [8].
2.4.5. CONSORT fulﬁlment and improvement
Uncertainty measures Compared to the previous research of Garcia et al [10] on
cross-over trials for the 2000− 2003 period, the proportion of papers that did not report
eﬀect size uncertainty remains almost constant in the years 2004 and 2007 but seems to
be slightly smaller in 2010 and 2013 (2000 − 2003: 45.0%, 18/40; 2004: 44.8%, 43/96;
2007, 44.1%, 49/111; 2010: 35.0%, 48/137; 2013: 39.7%, 50/126). But the percentage
of papers fulﬁlling the CONSORT statement items 15 and 17 [32] rises from 27.1%
(26/96, 2004) over 37.3% (41/110, 2007) to 39.4% (54/137, 2010) with a small decrease
to 34.1% (43/126, 2013), which is a statistically non-signiﬁcant yearly increment of 2.3%
(95%-CI: −7.3% to 11.9%, linear regression). This is in accordance with the positive
trend in reporting trial results observed by Piggot, Plint and Kane [33, 34, 35] after
the publication of CONSORT. However, these very low numbers indicate that there still
remains much room for improvement in reporting data variability.
In addition we recommend reporting the variability of the ﬁnal outcome in order to
obtain a reliable estimate of the correlation coeﬃcient.
Precision reporting uncertainty The same number of digits as the descriptive central
tendency (i.e., means) was also reported for the descriptive variability data (i.e., standard
deviation) and uncertainty measures (i.e., conﬁdence intervals).
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For example, Rosenquist et al. [36], in table 2 of their paper, reported the outcome
of the HAMD sleep factor score with just one single decimal for means and standard
deviations. Consequently an observed baseline standard deviation value of SDZ = 1.7
implies that 1.65 < SDZ < 1.75. Taking into account those extreme values a reported
coeﬃcient of 0.453, can in fact be obtained with any observed r value in the sample
between 0.389 and 0.510.
Designing clinical trials implies a compromise between actual and future patient rights.
Since more eﬃcient designs imply fewer recruited patients and earlier implementation
of their recommendations, the choice of the design, outcome and method of statistical
analysis plays a central role. But in order to design eﬃcient trials, we need to have
estimators of the correlation coeﬃcient. This implies that more accuracy is needed in
reporting variability and uncertainty than in reporting central tendency values. Recently,
the SAMPL guideline [37] states: For ease of comprehension and simplicity, round as
much as is reasonable. However, we have shown that reasonable should be interpreted
diﬀerently for tendency than for variability values. In further versions, we would like
reporting guidelines to address the topic of greater accuracy for variability values.
2.4.6. Challenges and limitations
Our main limitation is the large amount of papers (21.5%, 72/335) that do not report
both variability values. As any assumption can be made about those missing values,
uncertainty is much higher than that of conﬁdence intervals.
Another limitation is the use of baseline instead of outcome variance in some papers
(41.7%, 40/96). Although stability of variances holds at an average level, individual
values may be aﬀected. Furthermore, our analysis was based on an underlying model
that could be wrong. It has been suggested that correlations in active treatment groups
could be lower than in non-treatment groups [16]. This may be because the treatment
eﬀect is not constant, but variable; in which case, the measurement error estimation
would be biased.
Our work focused on studies without selection bias. What remains is a study of the
performance of those estimators, either in non-random studies or random studies with
missing data in which an equal baseline distribution cannot be guaranteed.
In summary, our study advises that trialists avoid absolute trust in published reliability
values when determining sample size. Additional implications may be: (1) reporting of
variability values should be improved so that future researchers can correctly employ
them in designing their own studies; (2) assumptions of homoscedasticity hold true in
general, but researchers should still assess whether they should persevere in their own
data; (3) baseline restriction further improves ANCOVA eﬃciency; and (4) there is
room for improving eﬃciency by controlling within patient variability  especially in
scales rated by observers.
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3. Part II
3.1. Introduction
Many randomized clinical trials use a repeated measures design in order to observe a
trend over time or to reduce the amount of subjects taking part in the study. In this case,
the clinical response is measured multiple times within the same subject. For example,
the electrical brain activity in diﬀerent areas can be measured with electroencephalog-
raphy (EEG) within the same subject. However, this simulation study only focuses on
repeated measures over time and in that case the term longitudinal data is also very
common.
Usually, the repeated measures within one subject have to be assumed to be correlated.
In that case, basic statistical methods as analysis of covariance, which are used for clini-
cal trials with only one baseline and one post-baseline measurement, are not applicable.
There are diﬀerent methods that can be applied to such a design including summary
statistics, repeated measures analysis of variance, linear mixed models and generalized
estimating equations.
For this simulation study, data of RCTs with repeated measures and a continuous, nor-
mally distributed primary outcome is simulated. Diﬀerent models are applied on the
simulated data and the goal is to investigate the performance of these models based
on the measures Power and Type I Error, Mean Square Error and coverage of the 95%
conﬁdence interval.
Chapter 3.2 describes the systematic literature search of RCTs with repeated measures
and a continuous outcome from the year 2014 to provide empirical estimates of the sim-
ulation parameters. After that the studied statistical models are presented in chapter
3.3 followed by the results and a discussion in chapter 3.4 and 3.5.
3.2. Simulation
3.2.1. Literature Review
In order to guide the simulation of the outcome data of a randomized clinical trial with
repeated measurements a literature review was performed. The target population of
the bibliographical search was randomized clinical trials with parallel groups, quantita-
tive primary outcome and repeated measurements published in 2014. For studies with
unspeciﬁed primary outcome, selected outcome was determined by the following hier-
archical criteria: (1) outcome on which sample size determination was based; (2) ﬁrst
reported outcome in results.
Diﬀerent approaches for the search strategy were developed, whereas (13) yielded the
most reasonable results and AB() means that the keywords have to appear in the ab-
stract, PD() speciﬁes the publication year and * searches for variations on a word that
are formed with diﬀerent suﬃxes. For example, random* ﬁnds occurrences of random,
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randomly, randomised and randomized. The search was performed in Medline.
AB((clinical trial* AND random*) AND (repeated measure* OR longitudinal))
AND PD(2014) (13)
Figure 5: Papers ﬂow diagram
The search was performed on 04.06.2015 and 295 papers were found. Figure 5 shows the
ﬂow diagram of papers. In order to reduce the amount of work, a sample of 100 papers
was drawn by means of the sample function in R [13] with a seed of 123456 which was
chosen before looking at the papers in order to avoid the risk of bias due to selective
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outcome reporting. Of the 100 papers 7 were theoretical works, 7 reported results of sec-
ondary measures of a RCT, 12 were descriptions of study designs without the reporting
of results, 15 were meta-analyses, 2 were trials in animals, 4 were observational studies
and 1 was a trial with only one treatment group. This left 52 RCTs of which 4 were
cross-over studies, 11 were RCTs with only two or less measurements per subject and
7 had a qualitative primary outcome. For 2 [38, 39] of the 30 papers that are part of
the target population, the full text version was not available without payment. 18 pa-
pers reported location and variability parameters for each time and treatment group, 3
reported location parameters only and 7 did not report any parameters. The references
of the 28 papers data was collected from can be found in appendix B.1.
The following variables were collected from the 28 papers if reported: title, authors,
journal, date of publication, primary outcome, number of groups, type of treatments,
number of control groups, number of measurements within subjects, times of measure-
ments, statistical method used for primary analysis, balanced design (yes/no), sample
size per group, number of subjects with missing data per group, missing measurements
per group, type of location and variability parameters reported, location and variability
parameters for each time and ﬁgure of eﬀect over time of primary outcome.
To control for the quality of the publishing journals, impact factor and subject category
were collected from Journal Citation Reports [40] and quartile rankings within subject
categories were determined. Q1 represents the top 25% journals of the subject category,
Q2 the middle-high position, Q3 the middle-low position and Q4 the bottom 25%. Only
papers published in a journal from Q1 or Q2 and with an impact factor ≥ 0.5 were
selected for guidance of the simulation parameters. This left 15 of the 28 papers.
Nr. Groups Measures Method Subjects M. subjects
35 2 3 rmANCOVA 75;75 18;17
38 2 4 GEE 6830;6758 2994;2922
66 2 3 LMM 30;30 1;2
69 2 3 LMM 26;28 11;6
100 2 5 ANOVA 40;40 NA
116 2 3 LMM 15;15 2;5
133 2 6 rmANOVA 57;57 2;3
162 2 5 ANCOVA 25;12 3;1
184 2 3 LMM 124;67 3;6
192 2 4 AUC,ANCOVA 237;238 10;21
197 2 4 rmANOVA 20;20 7;8
264 2 3 t-test 11;11 NA
273 2 3 rmANOVA 53;52 46 in total
278 2 5 Friedman's test 25;25 NA
287 2 5 rmANOVA 40;40 4;4
Table 4: Information on the 15 RCTs
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As an overview, table 4 provides details of the number of groups and measures, the
statistical method, the sample size per group and missing subjects per group (divided
by semicolon).
In 5 trials rmANOVA and rmANCOVA was used for analysing the primary outcome.
LMM was used 4 times, GEE, Friedman's test and the summary measure AUC combined
with ANCOVA one time each. In 3 papers each post-baseline measure was analysed
separately by ANOVA, ANCOVA or t-test. All trials had 2 groups and the number of
measurements varied from 3 to 6. The sample size per group ranged from 11 up to 6830
per group. The percentage of subjects with missing data varied from 0.0% up to 43.5%.
In 3 reports missing data was not addressed at all. Chapter 3.2.2 will provide more
descriptives for the results shown in table 4.
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Figure 6: Example of a constant eﬀect: (a) Eﬀect over time in both treatment groups;
(b) constant eﬀect over time between groups
In order to investigate the eﬀect over time, mean and standard deviation for each group
and time were plotted. Additionally, mean and standard deviation for the diﬀerence be-
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tween treatment groups for each time was plotted. Plots were created with the packages
ggplot2 [41] and gridExtra [42]. Some reports already provided a ﬁgure displaying the
eﬀect over time of the primary outcome. Most RCTs showed a constant or a linear eﬀect
over time.
Figure 6 shows the results of a RCT [43] with a constant eﬀect. The primary outcome
was pain score assessed by a visual analogue scale (VAS). On the horizontal axis time in
minutes is displayed and on the vertical axis pain score. There were ﬁve measures at 0,
1, 5, 15 and 30 minutes post treatment. Figure 7(a) shows mean and standard deviation
at each time for both groups and ﬁgure 7(b) shows the diﬀerence between groups at
each time. At baseline the means in both groups are more or less similar. The means in
the control group remain constant over time. For the ﬁrst post-baseline measure in the
treatment group a decrease from baseline can be observed. After that the means remain
constant in the treatment group.
Figure 7: Example of a linear eﬀect [44]
Figure 7 shows the results of a RCT [44] with a linear eﬀect. The primary outcome
was the Positive and Negative Syndrome Scale (PANSS) total score. On the horizontal
axis time in weeks is displayed and on the vertical axis the PANSS total score. There
were ﬁve measures at 0, 2, 4, 6 and 8 weeks. The two trial groups were Risperidone+L-
lysine (circles) and Risperidone+Placebo (triangles). In both groups PANSS total score
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decreases linearly over time, whereas the decrease in the Risperidone+L-lysine group is
larger.
3.2.2. Simulation Parameters
The choice of simulation parameters is mainly based on the results of the literature
review presented in chapter 3.2.1.
Table 5 shows the global simulation parameters that are equal for all settings. As
each trial has 2 randomized groups there are also 2 groups in all simulations. The
median number of repeated measures is 4 (i.e. 1 baseline and 3 post-baseline measures).
Although only some papers from the literature review showed a linear eﬀect over time,
only this eﬀect is considered for the simulations. For simplicity reasons, equidistant
times for the measurements are chosen. The number of iterations is 1000. That means
that 1000 data sets were simulated for each setting and each method was applied to
each data set. Consequently there are 1000 eﬀect measures for each method and each
simulation setting.
Randomized groups 2
Baseline measurements 1
Post-baseline measurements 3
Eﬀect over time linear
Times equidistant
Number of simulations 1000
Table 5: Global simulation parameters
Table 6 shows the varying simulation parameters that cause the diﬀerent settings. 13
of the 15 papers had balanced treatment groups. Therefore and based on the observed
sample sizes, balanced groups with sample sizes 25, 50 and 100 per group are simulated.
As the eﬀect over time is linear, the eﬀect size can be quantiﬁed by the diﬀerence of
slopes in the two groups. Without loss of generality, the slope in the control group is
set to be 0. Therefore the eﬀect size is equal to the slope in the experimental group. A
high (β = 1), medium (β = 0.5) and no eﬀect (β = 0) are chosen.
None of the papers reported correlation estimates for the repeated measures or infor-
mation on the correlation structure. 2 papers [45, 46] stated with which criterion the
correlation structure for the statistical method was determined but not which structure
was actually chosen in the end. Only 2 [47, 48] of the 15 papers (both had three repeated
measurements) reported variability for the change from baseline to the ﬁrst and second
post-baseline measure. This allowed the estimation of the correlation between baseline
and both post-baseline measures, but not between the two post-baseline measures.
To gain more insight on the correlation structure in randomized trials with repeated
measures, individual patient data from trials was retrieved. Although the beneﬁts of
publishing the data of a trial was discussed [49, 50, 51], it is still uncommon in practice
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[52, 53, 54]. Therefore data of only few trials could be collected.
These are a study by Ström et al [55, 56], McClellan et al [57, 58], Smailhodzic et al
[59, 60] and Vickers et al [61, 51]. By calculating the correlation matrices for each
quantitative outcome and treatment group from this data, the following main features
were observed: (1) sometimes there is a higher correlation between post-baseline mea-
sures than between baseline and a post-baseline measures; (2) correlations in the placebo
group are sometimes higher than in the experimental group and (3) sometimes the cor-
relation is decreasing with increasing time distance between measures. Still, a lot of
diﬀerent correlation structures were observed.
Number of subjects per group n = 25, 50, 100
Eﬀect size β = 0, 0.5, 1
Variance σ2 = 1, 9, 25
Random slope variance σ2R = 0, 0.01, 0.4
Correlation structure Independent; Exchangeable (0.85);
Exchangeable (0.65); Exchangeable
(0.45); AR1 (0.85); AR1 (0.65); AR1
(0.45); unstructured
Table 6: Varying simulation parameters
In order to maintain a reasonable amount of simulation settings, the following correlation
structures are simulated: (1) independent; (2) exchangeable with high correlation; (3)
exchangeable with medium correlation; (4) exchangeable with low correlation; (5) auto-
regressive of order 1 with high correlation; (6) auto-regressive with medium correlation;
(7) auto-regressive with low correlation and (8) unstructured. The correlation structure
is the same in treatment and control group.
The intensity of correlations 0.85 (high), 0.65 (medium) and 0.45 (low) is based on the
descriptives of the estimated initial-ﬁnal correlation from the meta-analysis described in
Part I. Those descriptives are shown in table 2. The unstructured correlation matrix is
displayed in (14). The correlation decreases with increasing time interval between the
measures, the correlation between baseline and post-baseline measures is smaller than
between two post-baseline measures and the correlation is not constant over time.
1 0.55 0.50 0.45
0.55 1 0.70 0.60
0.50 0.70 1 0.65
0.45 0.60 0.65 1
 (14)
Additionally, a random slope eﬀect for the subjects is simulated with the following
formula.
β +N(0, σ2R) (15)
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Here, β is the eﬀect size, which is equal to 0, 0.5 or 1 depending on the setting. A
normally distributed random eﬀect is added to the slope if σ2R > 0. The variance for the
random eﬀect is 0 (no random eﬀect), 0.01 or 0.4.
The signal-to-noise ratio (also called standardized eﬀect), calculated by dividing the
eﬀect size β by the noise which is the square root of the sum of σ2 and σ2R, is an
indicator for the magnitude of the eﬀect size. Values of 0.2, 0.4 and 0.8 are considered
as low, medium and large eﬀect size [62]. These values are well represented by the chosen
simulation parameters for β, σ and σR as can be seen in table 7.
β σ2 σ2R Signal-to-noise ratio
0 1, 9 or 25 0, 0.01 or 0.4 0
0.5 1 0 0.500
0.5 1 0.01 0.498
0.5 1 0.4 0.423
0.5 9 0 0.167
0.5 9 0.01 0.167
0.5 9 0.4 0.163
0.5 25 0 0.100
0.5 25 0.01 0.100
0.5 25 0.4 0.099
1 1 0 1.000
1 1 0.01 0.995
1 1 0.4 0.845
1 9 0 0.333
1 9 0.01 0.333
1 9 0.4 0.326
1 25 0 0.200
1 25 0.01 0.200
1 25 0.4 0.198
Table 7: Signal-to-noise ratio for the simulations settings
3.2.3. Performance Measures
For each simulation setting, data was simulated 1000 times. The statistical methods
were applied to the 1000 data sets per setting. The following results were saved for each
application of a statistical method: (1) p-value of the interaction between treatment
group and time; (2) eﬀect size, i.e. estimated coeﬃcient for the interaction and (3)
standard error of the estimated coeﬃcient.
The primary performance measure is the empirical power in case there is a treatment
eﬀect (β = 0.5, 1) or the empirical Type I Error in case there is no treatment eﬀect
(β = 0). Both are calculated by dividing the amount of signiﬁcant p-values by the
amount of simulations in total, i.e. 1000.
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Secondary performance measures are: (1) mean square error to measure the overall error
rate of the point estimator and (2) empirical coverage of 95% conﬁdence interval around
the estimated eﬀect, i.e. the ratio of conﬁdence intervals that include the true eﬀect.
Besides the descriptive interpretation of the results, linear models are applied to the
performance measures. For each correlation structure and eﬀect size, a linear regression
is computed with the performance measure as dependent variable and the simulation
parameters sample size, residual variance, random slope variance and type of model as
independent variables. Also, interactions between sample size, residual variance and
random slope variance are included.
3.3. Methods
3.3.1. Summary measures
Notation
For chapters 3.3.1 and 3.3.2, the notation has to be speciﬁc to treatment groups. Let
there be h = 1, ..., s groups, i = 1, ..., nh subjects per group, N =
∑s
h=1 nh subjects
in total, ni measures per subject and t = 1, ..., ni. Therefore yhit is the measurement
for subject i from group h at time t. The times at which measurements are taken are
z1, ..., zni .
Summary measures
The concept of summary measures is to combine all post-treatment measures of a sub-
ject to one single value. This has the advantage that the statistical analysis does not
have to account for the dependency between measures within a subject.
There are several approaches for summarizing the measures including mean of all mea-
sures, slope of the measures, the area under the curve (AUC), maximum measure or
time to maximum. The choice of summary statistic depends on the speciﬁc research
question. Here, only mean and slope are introduced.
Usually after calculating the summary measures, there is one baseline and one post-
treatment value left for each subject. In that case the treatment eﬀect can be estimated
by one of three methods jointly modeled as τ(b) = (Y¯1− Y¯0)− b(Z¯1− Z¯0) [6]. Depending
upon the value of b, we obtain either the ﬁnal estimator τˆ(0), the change score τˆ(1)
or the analysis of covariance (ANCOVA) τˆ(β). As shown in chapter 2.1 and [63], the
ANCOVA is the most powerful method of the three.
Mean summary statistics (16) are usually applied when the objective is to determine the
average treatment eﬀect over time and the eﬀect is assumed to appear before the ﬁrst
post treatment measurement and remains constant hereafter [7].
smmean,hi =
1
ni − 1
ni∑
t=2
yhit (16)
If a linearly divergent eﬀect is assumed a linear summary statistic should be used. In
[1] the so called statistics SLANC and SLAIN are introduced. For both, the slope (17)
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of the post treatment values of a subject is used as a summary measure.
smslope;hi =
∑ni
t=2(zt − z¯)yhit∑ni
t=2(zt − z¯)2
(17)
The idea of SLANC (a SLOPE-based ANCOVA) is to use the slope as the dependent
variable and the baseline measure as a covariate in an ANCOVA. SLAIN (a SLOPE-
based ANCOVA with INTERCEPT as covariate) is very similar to SLANC with the
distinction that the estimated intercept of each subject is used as a covariate instead
of the baseline measure. Under the assumption of true linear divergence, compound
symmetry correlation structure, equidistant time intervals between measures and one
baseline measure, it can be shown that SLAIN has a lower variance than SLANC as the
variance of the intercept is always lower than the variance of the baseline measure [1].
In case of missing data the summary statistics should be weighted accordingly.
Analysis of covariance
If there is a linear relationship between the baseline measure and the summary measure,
the ANCOVA (18) is an appropriate model.
smhi = µ+ τh + β(yhi1 − y¯..1) + hi (18)
Here, smhi is the summary measure and yhi1 the baseline measure for subject i in group
h, y¯..1 is the mean of the baseline measure over all subjects, µ is an overall mean, τh the
treatment eﬀect, β is a linear regression coeﬃcient describing the relationship between
smhi and yhi1 and hi is the random error.
Further assumptions are that β 6= 0, the true relationship between summary and baseline
measure is linear, β is equal for all treatment groups, the treatment eﬀects τh sum up
to zero and the random errors are independently normally distributed (19). So that µ
is an overall mean, β(yhi1 − y¯..1) is used instead of βyhi1.
hi
iid∼ N(0, σ2) (19)
In an ANCOVA, the dependent variable is ﬁrst adjusted by the covariates and after the
eﬀect of the factor variables is examined. Further details on estimation and inference
are provided in [64].
In the simulation study, the more simple approach SLANC is used.
3.3.2. Repeated Measures ANOVA
In the case of normally distributed data and independent measurements the analysis of
variance (ANOVA) is a common approach. To account for repeated measurements a
repeated measures ANOVA (rmANOVA) is performed. First, a standard ANOVA is ap-
plied and second, it is examined if additional assumptions or modiﬁcations are required
to make the analysis valid. It is not necessary to model the covariance structure with this
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approach. However, diﬀerent methods as the Linear Mixed Model (see Chapter 3.3.3)
require less strict assumptions and oﬀer thrifty modeling of the covariance structure [2].
In general, a clinical study includes more than one group and therefore only the multi-
sample problem is described here.
Let there be h = 1, ..., s groups, i = 1, ..., nh subjects per group, N =
∑s
h=1 nh subjects
in total, T measures per subject and t = 1, ..., T . Therefore yhit is the measurement for
subject i from group h at time t. In contrast to the previous chapter, the number of
measures per subject T is constant.
The model can be written as follows.
yhit = µ+ γh + τt + (γτ)ht + pii(h) + hit (20)
In (20) µ is the overall mean, γh is the ﬁxed eﬀect of group h, τt is the ﬁxed eﬀect of time
t, (γτ)ht is the ﬁxed eﬀect of the interaction of group h and time t, pii(h) is the random
eﬀect of subject i in group h and hit is the random error of subject i in group h at time
t.
Assumptions for these parameters are displayed in (21-25).
s∑
h=1
γh = 0 (21)
T∑
t=1
τt = 0 (22)
s∑
h=1
(γτ)ht =
T∑
t=1
(γτ)ht = 0 (23)
pii(h)
ind∼ N(0, σ2pi) (24)
hij
ind∼ N(0, σ2 ) (25)
Because of the individual diﬀerence component for subject i in treatment group h (24)
and the error for subject i in group h at time j (25), the repeated measures are assumed
to follow an exchangeable (also called compound symmetry) structure. Therefore the
covariance matrix is written as (26). Compound symmetry is a special case of sphericity
which says that the variances of the diﬀerences of all possible pairs of subjects have to
be equal, i.e. V ar(yij − yij′) = const. ∀j, j′. If sphericity does not hold, the F tests are
usually too liberal. Another limitation is that it only works with balanced data. If only
one observation is missing, the subject has to be dropped.
σ2pi + σ
2
 σ
2
pi · · · σ2pi σ2pi
σ2pi σ
2
pi + σ
2
 σ
2
pi · · · σ2pi
... σ2pi
. . . . . .
...
σ2pi
...
. . . . . . σ2pi
σ2pi σ
2
pi · · · σ2pi σ2pi + σ2
 (26)
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The sums of squares for all the sources of variation [2] are based on the divergence of
each observation from the overall mean y¯... (27).
yhit − y¯... =(y¯h.. − y¯...) + (y¯hi. − y¯h..) + (y¯..t − y¯...)+
(y¯h.t − y¯h.. − y¯..t + y¯...) + (y¯hit − y¯h.t − y¯hi. + y¯h..) (27)
In (27) y¯h.. is the mean for group h, y¯..t is the mean at time t, y¯h.t is the mean for group
h at time t and y¯hi. is the mean of subject i in group h. From that the deﬁnitions of the
sum of squares result for the source group (28), subjects (29), time (30), group x time
(31) and residual (32).
SSG =
s∑
h=1
nh∑
i=1
T∑
t=1
(y¯h.. − y¯...)2 = T
s∑
h=1
nh(y¯h.. − y¯...)2 (28)
SSS(G) =
s∑
h=1
nh∑
i=1
T∑
t=1
(y¯hi. − y¯h..)2 = T
s∑
h=1
nh∑
i=1
(y¯hi. − y¯h..)2 (29)
SST =
s∑
h=1
nh∑
i=1
T∑
t=1
(y¯..t − y¯...)2 = N
T∑
t=1
(y¯..t − y¯...)2 (30)
SSGT =
s∑
h=1
nh∑
i=1
T∑
t=1
(y¯h.t − y¯h.. − y¯..t + y¯...)2 (31)
SSR =
s∑
h=1
nh∑
i=1
T∑
t=1
(yhit − y¯h.t − y¯hi. + y¯h..)2 (32)
As can be seen, SSG, SST and SSGT are the same as for a two-way ANOVA with
interaction which assumes independence among measurements. However, SSR is nested
within the cross-classiﬁcation of group x time due to the subject eﬀect.
Table 8 shows the sum of squares (SS), degrees of freedom (df) and expected mean sum
of squares (MS) for each source of variation in the data, whereas DG, DT and DGT
represent diﬀerences among groups, times and group x time interaction.
Source SS df E(MS)
Group SSG s− 1 σ2 + tσ2pi +DG
Subjects(Group) SSS(G) N − s σ2 + tσ2pi
Time SST T − 1 σ2 +DT
Group x Time SSGT (s− 1)(T − 1) σ2 +DGT
Residual SSR (N − s)(T − 1) σ2
Table 8: Sum of squares (SS), degrees of freedom (df) and expected mean sum of squares
(MS) for each source of variation
The test of primary interest (33) is the testing for group by time interaction with the
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following F-statistic (34).
HGT : DGT = 0 (33)
FGT =
MSGT
MSR
=
SSGT/[(s− 1)(T − 1)]
SSR/[(N − s)(T − 1)]
HGT∼ F(s−1)(T−1),(N−s)(T−1) (34)
If this null hypothesis is rejected the group diﬀerences are not the same across time, the
group curves across time are not parallel and the group and time eﬀects are confounded
with the interaction and cannot be separately tested.
If the null hypothesis is accepted we can test for the time (35-36) and group eﬀect (37-38)
separately and independently.
HT : τ1 = ... = τT = 0 (35)
FT =
MST
MSR
=
SST/(T − 1)
SSR/[(N − s)(T − 1)]
HT∼ FT−1,(N−s)(T−1) (36)
HG : γ1 = ...γs = 0 (37)
FG =
MSG
MSS(G)
=
SSG/(s− 1)
SSS(G)/(N − s)
HG∼ Fs−1,N−s (38)
For all three tests the within-group covariance matrices have to be equal. Additionally
for the test for the interaction and the time eﬀect the sphericity assumption has to be
met.
3.3.3. Linear Mixed Models
Notation
In contrast to the two previous chapters, the notation is not speciﬁc to treatment groups
anymore. Therefore, letN be the number of subjects and ni the number of measurements
of subject i, i = 1, ..., N . The vector yi = (yi1, ..., yini) contains the measurements of
subject i, i = 1, ..., N and t = 1, ..., ni.
Model
Linear mixed models (LMM) are well known and applied in a lot of areas. It is written
as follows [3].
Yi = Xiβ + Zibi + i (39)
In model (39) Xi is the ni x p design matrix of ﬁxed eﬀects of subject i, β is the p x 1
coeﬃcient vector, Zi is the ni x q design matrix of random eﬀects of subject i, bi is the
q x 1 vector of random eﬀects of subject i and i is the ni x 1 vector of within-subject
errors.
The bi and i are independent and follow a multivariate normal distribution. Conse-
quently the yi, that is the measurements of diﬀerent subjects, are independent too.
bi ∼ Nq(0q, B) (40)
i ∼ Nni(0ni ,Wi) (41)
yi ∼ Nni(Xiβ, ZiBZ ′i +Wi) (42)
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Assumptions for the structures of B (40) and Wi (41) have to be made, whereas Wi
only depends on i through the number of measurements ni. Obviously B, that is the
correlation between random eﬀects, has only to be speciﬁed if there are two or more
random eﬀects.
The dependent variable yi follows a linear regression whereby β are coeﬃcients speciﬁc to
the population and the random eﬀects bi speciﬁc to the subjects. Therefore the variabil-
ity of the data is split into two sources. The deviation of a subject from the population
mean and the deviation of a measurement from the respective subject mean.
Covariance structure of the residuals
A widespread model for the covariance structure of the residuals is that the individual
vector i has a constant variance and can be split into
i = (1)i + (2)i, (43)
whereas (2)i represents the serial correlation which normally decreases with the distance
between measurements and (1)i represents the random error and is independent from
(2)i.
Therefore we have the following model.
(1)i ∼ N(0ni , σ2Ini) (44)
(2)i ∼ N(0ni , τ 2Hi) (45)
For the ni x ni serial correlation matrix Hi, a structure has to be assumed. Usually the
serial eﬀect (2)i is assumed to be independent from the speciﬁc subject. Consequently
Hi only depends on i through the number of measurements ni.
The package nlme [65] in R [13] includes ten available correlation structures. They are
described in [66]. Here, only the very commonly used structures compound symmetry,
unstructured and auto-regressive of order 1 are explained. All matrices are displayed
as 5 x 5. In the case of more or less than ﬁve repeated measures the dimension of the
matrices has to be adjusted accordingly.
The compound symmetry correlation structure does not depend on the time of the
observation, which means that the correlation between all times is equal (46). Therefore
it is also called exchangeable structure. The main advantage of this structure is that
only one parameter needs to be estimated. However, the assumption that the correlation
between more distant observations is as high as the correlation between close observations
might be unreasonable in many cases.
1 ρ ρ ρ ρ
ρ 1 ρ ρ ρ
ρ ρ 1 ρ ρ
ρ ρ ρ 1 ρ
ρ ρ ρ ρ 1
 (46)
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The general correlation structure allows every correlation parameter to be diﬀerent (47).
It is also called unstructured correlation. Its biggest disadvantage is that ni(ni−1)
2
pa-
rameters have to be estimated.
1 ρ21 ρ31 ρ41 ρ51
ρ21 1 ρ32 ρ42 ρ52
ρ31 ρ32 1 ρ43 ρ53
ρ41 ρ42 ρ43 1 ρ54
ρ51 ρ52 ρ53 ρ54 1
 (47)
The auto-regressive correlation structure of order 1 assumes that the correlation de-
creases with increasing distance |t− t′| between measures. Only one parameter needs to
be estimated. The correlation between yit and yit′ is calculated by
cor(yit, yit′) = ρ
|t−t′|, (48)
which leads to the correlation matrix (49).
1 ρ|t−t
′| ρ|t−t
′| ρ|t−t
′| ρ|t−t
′|
ρ|t−t
′| 1 ρ|t−t
′| ρ|t−t
′| ρ|t−t
′|
ρ|t−t
′| ρ|t−t
′| 1 ρ|t−t
′| ρ|t−t
′|
ρ|t−t
′| ρ|t−t
′| ρ|t−t
′| 1 ρ|t−t
′|
ρ|t−t
′| ρ|t−t
′| ρ|t−t
′| ρ|t−t
′| 1
 (49)
Estimation
The estimation of the parameters in the linear mixed model is described in [67].
Let θ be the vector of all variance and covariance parameters involved in the covariance
matrix of yi (42). That includes the parameters in D and Wi. We write
Vi(θ) = ZiBZ
′
i +Wi. (50)
The model (39) can be written in matrix form with
y = (y1, y2, ..., yN)
′ (51)
X = (X1, X2, ..., XN)
′ (52)
b = (b1, b2, ..., bN)
′ (53)
V (θ) = diag(V1(θ), V2(θ), ..., VN(θ)) (54)
B˜ = diag(B,B, ..., B) (55)
Z = diag(Z1, Z2, ..., ZN) (56)
W = diag(W1,W2, ...,WN) (57)
which leads to the marginal distribution
y ∼ N(Xβ, V (θ)) = N(Xβ,ZB˜Z ′ +W ). (58)
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If B˜ and W are known, β and b can be estimated by the generalized least squares
estimators (59-60).
βˆ(θ) = (X ′V (θ)−1X)−1X ′V (θ)−1y (59)
bˆ(θ) = D˜Z ′V (θ)−1(y −Xβˆ(θ)) (60)
The maximum likelihood estimators are obtained by maximizing the log-likelihood (61)
of (58) for β and θ. For clarity reasons, only the non-constant part of the log-likelihood
is displayed.
lML(β, θ|y) = −1
2
log(|V (θ)|)− 1
2
(y −Xβ)′V (θ)−1(y −Xβ) (61)
By maximizing (61) for β, we obtain (59) and θ is estimated by maximizing the likelihood
(ML) or the restricted likelihood (REML).
The ML estimator of θ is biased downwards because it does not account for the loss of
degrees of freedom due to the estimation of the unknown β. This is the motivation for
the REML estimator.
The idea is to estimate θ directly without involving the expected value Xβ. This is
accomplished by introducing a linear transformation of y, u = A′y, which is called error
contrast. In the case of the linear mixed model this leads to the following log-likelihood
(only non-constant part).
lREML(βˆ(θ), θ|y) = −1
2
log(|X ′V (θ)−1X|) + lML(βˆ(θ), θ|y) (62)
In conclusion θ is estimated by maximizing (61) or (62) and β by (59). The ML or
REML estimators are calculated by the expectation-maximization (EM) or Newton-
Raphson (NR) algorithm [67].
Inference
Statistical tests can be applied to the ﬁxed eﬀects and the variance parameters. The
prediction of the random eﬀects serves the interpretation and the prediction of the
subject speciﬁc behavior.
For the ﬁxed eﬀects, the hypotheses are (63). For example, if L = ( 1 −10 0 ) and β =
(β1, β2)
′, then the null hypothesis is β1 − β2 = 0.
H0 : Lβ = 0 vs. H1 : Lβ 6= 0 (63)
The nlme package uses the wald test. It is based on the fact that
(βˆj − βj)
se(βˆj)
(64)
is approximately normally distributed. Under the null, the test statistic T (65) is ap-
proximately χ2 distributed with rang(L) degrees of freedom.
T = (βˆ − β)′L′
L( N∑
i=1
X ′iVi(αˆ)
−1Xi
)−1
L′
−1 L(βˆ − β) (65)
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Main diﬀerences between rmANOVA and LMM
While rmANOVA uses sums of squares, linear mixed models use restricted maximum
likelihood estimation. Also, the mixed model approach is more ﬂexible about interactions
(rmANOVA forces interactions with within-subject variable) and correlation structures
(rmANOVA always assumes compound symmetry). Linear mixed models can handle
missing data whereas rmANOVA drops every subject that has missing observations.
Also, they can characterize ﬁxed (group) and random (individual) eﬀects in a formal
way and include additional covariates. While time has to be entered as a factor in a
rmANOVA, it can be treated as a continuous variable with a LMM which means that
subjects can enter the study at diﬀerent times.
3.3.4. Generalized Estimating Equations
Model
Generalized Estimating Equations (GEE) were introduced by Liang and Zeger [4] for
the analysis of longitudinal data as an extension of generalized linear models. Their
primary goal was to provide a method for the analysis of non-Gaussian longitudinal
data. However, it makes sense to apply GEE to normal data, for example when the
covariance structure is unknown.
The generalized linear model (GLM) can be used for the analysis of cross-sectional data
only. The conditional distribution of yi|xi is assumed to be from the exponential family.
A less restrictive approach is quasi-likelihood. Here assumptions are only made about
the expected value and the variance. If there are doubts about the variance of yi|xi the
GEE approach can be used. Only the expected value is assumed to be speciﬁed correctly
and for the variance a working variance is assumed which does not have to be the true
variance.
In order to apply GEE to longitudinal data, they have to be combined with a marginal
model in which the marginal expected values of the correlated dependent variables are
modeled in dependence of the covariates. In that case the expected value and the
variance are assumed to be speciﬁed correctly whereas a working correlation is assumed.
The concept can be described in three steps. The expected value of the dependent
variable µit = E(Yit|Xit) is related to a linear combination of the covariates (66), whereas
yit is the outcome of individual i at time point t, xit is a p x 1 vector of covariates of i
at time point t, β is a p x 1 vector of unknown regression coeﬃcients and g(.) is a link
function.
g(µit) = x
′
itβ, t = 1, ..., T (66)
The variance (67) consists of a known function ν of the expected value and a possibly
unknown scale parameter φ.
V ar(Yit|Xit) = ν(µit)φ (67)
The next step is to choose a TxT working covariance matrix with the unknown parameter
vector α and the chosen function c.
cov(yij, yis) = c(µij, µis, α), i 6= s (68)
29
Common structures are compound symmetry, unstructured and auto-regressive of order
1 as described in chapter 3.3.3.
In the case of normal distributed dependent variables the link function g(µit) = µit, the
function ν(µit) = 1 and the variance V ar(Yit) = φ, whereas φ is unknown.
Estimation
The solution of the generalized estimating equations (69) provides the estimation of the
regression parameter β.
N∑
i=1
(
∂µi
∂β
)′
V −1i (yi − µi) = 0 (69)
Vi = A
1/2
i RiA
1/2
i (70)
Ai = diag(φν(µi1), ..., φν(µini)) (71)
The p x ni matrix
(
∂µi
∂β
)′
solely depends on β and Ai(β) results from the model assump-
tions. However, assumptions have to be made for the correlation matrix Ri(α).
In short, the algorithm for solving the generalized estimating equations can be described
in four steps: 1) run a generalized linear model (GLM) with the assumptions of inde-
pendence of measurements to obtain initial values for β, 2) with β, calculate Ai(β), αˆ
and φˆ, 3) derive Ri(α) and 4) update β. Steps 2 until 4 are iteratively repeated until
convergence is met.
In order to calculate the parameters in step 2, the residuals have to be calculated using
the current β.
rit(β) =
yit − µit(β)√
ν(µit(β))
(72)
The estimation of α depends on the structure of Ri(α). In the case of an exchangeable
structure it is obtained by (73) and in case of an autoregressive structure of order 1 it
is obtained by (74).
αˆ =
1
Nφˆ
N∑
i=1
1
ni(ni − 1)
∑
t6=t′
ritrit′ (73)
αˆ =
1
Nφˆ
N∑
i=1
1
ni − 1
∑
t≤ni−1
ritri,t+1 (74)
The parameter φ is estimated by (75).
φˆ =
1
N
N∑
i=1
1
ni
ni∑
t=1
r2it (75)
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The correlation matrix Ri(α) is obtained depending on the structure with the currently
estimated α. In the forth step β is updated with the following formula.
βnew = βold −
[
N∑
i=1
(
∂µi
∂β
)′
V −1i
(
∂µi
∂β
)]−1 [ N∑
i=1
(
∂µi
∂β
)′
V −1i (yi − µi)
]
(76)
The general linear hypothesis for the β coeﬃcients can be examined with the Wald test.
3.3.5. Application of Methods
On each data set, fourteen diﬀerent models were applied.
Because a linear eﬀect is simulated, the slope of all post-measures of a subject was used
as a summary measure. After, an analysis of covariance was applied with the slope as
dependent variable, the treatment as factor and the baseline measures as a covariate
(SLANC).
Repeated-measures ANOVA was applied with the within subject factor time and the
between subject factor treatment. This is the only method which does not provide an
eﬀect measure, but only a p-value. The ezANOVA function from the ez -package [68]
was used.
Generalized Estimating Equations were applied with the eﬀects time, treatment and
the interaction between treatment and time by means of the gee function from the gee-
package [69]. The method was applied four times with the four diﬀerent correlation
structures unstructured, independent, exchangeable and auto-regressive of order 1.
The linear mixed model was modeled eight times. Also with the four diﬀerent correlation
structures and for each structure without random eﬀects and with a random slope eﬀect.
With random eﬀects was calculated with the lme function and without random eﬀect
with the gls function as it can be viewed as the same function without random eﬀects
[70]. Both functions are from the nlme-package [65].
3.4. Results
As there are 648 (3 sample sizes x 3 eﬀect sizes x 3 residual variances x 3 random slope
variances x 8 correlation structures) diﬀerent simulation settings, not all results can be
displayed here by means of ﬁgures. However, the relevant results will be described and
all results can be found in the Electronic Appendix described in Appendix C. All plots
were created with the package ggplot2 [41]. To further explore the results, there is a
possibility to work with dynamic plots created with the package manipulate [71] which
is also explained in the Electronic Appendix.
The correlation structures will be abbreviated as follows: Ind for independent, ExcLow
for exchangeable with low correlation, ExcMed for exchangeable with medium correla-
tion, ExcHigh for exchangeable with high correlation, ArLow for auto-regressive with
low correlation, ArMed for auto-regressive with medium correlation, ArHigh for auto-
regressive with high correlation and Uns for unstructured correlation matrix.
The diﬀerent applied models will be abbreviated as follows: summary for the summary
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statistic SLANC, rmANOVA for repeated measures analysis of variance, gee_ind for
GEE assuming independent repeated measures, gee_exc for GEE assuming exchange-
able correlation structure, gee_ar for GEE assuming auto-regressive structure, gee_uns
for GEE assuming unstructured correlation, lmm_ind for linear mixed model assuming
independent repeated measures, lmm_exc for linear mixed model assuming exchange-
able correlation structure, lmm_ar for linear mixed model assuming auto-regressive
structure and lmm_uns assuming unstructured correlation. The suﬃx _rand is added
to the abbreviation of the linear mixed models if a random slope eﬀect was modelled.
Besides the descriptive interpretation of the results supported by ﬁgures and tables, lin-
ear models are applied to the performance measures. For each correlation structure and
eﬀect size, a linear regression is computed with the performance measure as dependent
variable and the simulation parameters sample size, residual variance, random slope
variance and type of model as independent variables. Also, interactions between sample
size, residual variance and random slope variance are included.
3.4.1. Primary performance measure: Power / Type I Error
Independent correlation
In this paragraph the results for the simulated data with independent repeated mea-
surements are presented. Figure 8 shows the results for Ind and β = 0.5. The strength
of the power in this heat map is represented as colors from white to steelblue whereas
white means low and steelblue high power. The plot contains nine matrices, one for each
σ2-σ2R combination. The sample size is plotted on the horizontal axis and the method
on the vertical axis. Therefore all simulation results for β = 0.5 and Ind are shown in
this plot.
The mean power signiﬁcantly increases with the sample size (coeﬃcient estimate: βˆn =
0.0028; 95%-CI: 0.0020 to 0.0036) from 0.424 (n = 25) over 0.534 (n = 50) to 0.672
(n = 100). On the other hand it signiﬁcantly decreases with the residual variance
(βˆσ2 = −0.0309; −0.0341 to −0.0277) from 0.960 (σ2 = 1) over 0.456 (σ2 = 9) to 0.215
(σ2 = 25) and the random slope variance (βˆσ2R = −0.2246; −0.4117 to −0.0375) from
0.550 (σ2R = 0) over 0.555 (σ
2
R = 0.01) to 0.525 (σ
2
R = 0.4). There are no signiﬁcant
interactions between the simulation parameters. All models show a signiﬁcantly higher
power than the reference model summary.
The method summary has the lowest power for the 27 settings and rmANOVA has the
second lowest power except for (σ2 = 1;σ2R = 0.4;n = 25, 50, 100), where gee_uns has
the second lowest and rmANOVA the third lowest power.
For (σ2 = 1;σ2R = 0;n = 25, 50, 100), (σ
2 = 1;σ2R = 0.01;n = 25, 50, 100) and
(σ2 = 1;σ2R = 0.4;n = 100) the power is equal to or slightly lower than 1 for all
methods. For example, for (σ2 = 1;σ2R = 0;n = 25) the power only ranges from 0.978
to 0.981 apart from rmANOVA (0.923) and summary (0.682).
For (σ2 = 1;σ2R = 0.4;n = 25, 50), lmm_exc shows the highest power. Also, lmm_uns,
lmm_ind_rand, lmm_exc_rand, lmm_ind, lmm_uns_rand and lmm_ar_rand show a
large power. The four GEE models, rmANOVA and summary show the lowest power.
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Figure 8: Power for Ind and β = 0.5
If we increase the variance σ2, i.e. (σ2 = 9;σ2R = 0.4;n = 25, 50, 100) the GEE models
perform better. For n = 25 gee_uns, gee_exc, gee_ind, lmm_exc, gee_ar and lmm_uns
are the best methods. For n = 50 and n = 100 lmm_ar_rand and lmm_exc peform
best but the GEE models are still considerably better than for σ2 = 1.
For (σ2 = 9;σ2R = 0;n = 25, 50, 100) and (σ
2 = 9;σ2R = 0.01;n = 25, 50, 100) gee_uns
has the highest power, except for the setting (σ2 = 9;σ2R = 0;n = 100) where the power
is 0.002 points lower than with lmm_uns. Also gee_exc, gee_ind and gee_ar perform
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very well in these scenarios and in almost every case better than the linear mixed models.
If we further increase the variance to σ2 = 25 these results are conﬁrmed. For (σ2 =
25;σ2R = 0.4;n = 25, 50, 100) the GEE models further improve compared to (σ
2 =
9;σ2R = 0.4;n = 25, 50, 100) and have the highest power for n = 25 and n = 50.
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Figure 9: Type I Error for Ind and β = 0
In summary, rmANOVA and summary perform worst if the repeated measurements are
uncorrelated. With a low residual variance and a high random slope variance the linear
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mixed models, especially lmm_exc, perform better than the GEE models. However,
with increasing residual variance this is no longer the case and the GEE models improve
compared to the linear mixed models. If there is no or a low random slope eﬀect the
GEE models, especially gee_uns, perform better than the linear mixed models. With
β = 1 the power is globally higher but the results concerning the comparison of the
diﬀerent models are the same as with β = 0.5.
Figure 9 shows the results for β = 0, i.e. no eﬀect. In this case the primary performance
measure is the Type I Error.
Figure 10: Interaction plot of residual variance and random slope variance for Ind and
β = 0
The mean Type I Error signiﬁcantly decreases with the sample size (βˆn = −0.0001;
−0.0002 to −0.0001) from 0.061 (n = 25) over 0.056 (n = 50) to 0.049 (n = 100). It
decreases with the residual variance from 0.058 (σ2 = 1) over 0.054 (σ2 = 9) to 0.055
(σ2 = 25), but this trend is not statistically signiﬁcant. It signiﬁcantly increases with
the random slope variance (βˆσ2R = 0.0344; 0.0235 to 0.0452) from 0.052 (σ
2
R = 0) over
0.056 (σ2R = 0.01) to 0.058 (σ
2
R = 0.4). Also, there is a signiﬁcant interaction between
residual variance and random slope variance (βˆσ2∗σ2R = −0.0008; −0.0013 to −0.0004)
because the power increases more rapidly with the random slope variance for σ2 = 1
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than for σ2 = 9, 25 as can be seen in ﬁgure 10 and sample size and random slope variance
(βˆn∗σ2R = −0.0002; −0.0004 to −0.0001) because the power increase with the random
slope variance for n = 25, 50 but is lowest for σ2R = 0.01 if n = 100. There is no sig-
niﬁcant interaction between residual variance and sample size. All models except for
rmANOVA show a signiﬁcantly higher Type I Error than the reference model summary.
The method summary has the lowest or second lowest Type I Error in 19 and a Type
I Error equal to or lower than 0.05 in 21 of the 27 settings. Although rmANOVA has
the second-lowest power, it has a Type I Error above the third quartile in 7 of the 27
settings.
For a high random slope variance σ2R = 0.4, lmm_exc (0.075), lmm_uns (0.072),
lmm_ar_rand (0.066), lmm_ind_rand (0.066) and gee_uns (0.064) have the highest
errors. In case of σ2R = 0 or σ
2
R = 0.01 gee_uns (0.061), gee_exc (0.057), gee_ind (0.057)
and gee_ar (0.057) have the highest errors. The errors of the linear mixed models range
from 0.052 to 0.056. Table 9 shows the average of the Type I Error for each method
stratiﬁed by σ2R = 0, 0.01 and σ
2
R = 0.4.
σ2R = 0, 0.01 σ
2
R = 0.4
Method Type I Error Method Type I Error
gee_uns 0.061 lmm_exc 0.075
gee_exc 0.057 lmm_uns 0.072
gee_ind 0.057 lmm_ar_rand 0.066
gee_ar 0.057 lmm_ind_rand 0.066
lmm_uns 0.056 gee_uns 0.064
lmm_uns_rand 0.056 lmm_uns_rand 0.060
lmm_ar_rand 0.055 lmm_exc_rand 0.058
lmm_exc 0.054 lmm_ind 0.057
lmm_ind_rand 0.054 lmm_ar 0.055
lmm_ar 0.053 gee_exc 0.055
lmm_ind 0.053 gee_ind 0.055
lmm_exc_rand 0.052 gee_ar 0.054
rmANOVA 0.047 rmANOVA 0.045
summary 0.046 summary 0.045
Table 9: Mean Type I Error for each method for β = 0 and Ind stratiﬁed by σ2R
Exchangeable correlation
In this paragraph the results for the simulated data with exchangeable correlation be-
tween the repeated measures are presented. Figure 12 shows the results for β = 0.5
and ExcLow. The strength of the power in this heat map is represented as colors from
white to steelblue whereas white means low and steelblue means high power. The plot
contains nine matrices, one for each σ2-σ2R combination. The sample size is plotted on
the horizontal axis and the method on the vertical axis. Therefore all simulation results
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for β = 0.5 and ExcLow are shown in this plot.
The mean power signiﬁcantly increases with the sample size (βˆn = 0.0026; 95%-CI:
0.0019 to 0.0033) from 0.480 (n = 25) over 0.607 (n = 50) to 0.772 (n = 100). On the
other hand it signiﬁcantly decreases with the residual variance (βˆσ2 = −0.0339; −0.0368
to −0.0311) from 0.978 (σ2 = 1) over 0.595 (σ2 = 9) to 0.286 (σ2 = 25) and the random
slope variance (βˆσ2 = −0.1788; −0.3422 to −0.0153) from 0.630 (σ2R = 0) over 0.632
(σ2R = 0.01) to 0.596 (σ
2
R = 0.4). Also, there is a signiﬁcant interaction between residual
variance and sample size (βˆσ2∗n = 0.0001; 0.0001 to 0.0001) because the power increases
more rapidly with the sample size for σ2 = 9, 25 than for σ2 = 1 as can be seen in ﬁgure
11. There is no signiﬁcant interaction between residual variance or sample size and ran-
dom slope variance. All models except for lmm_ind, lmm_ar and lmm_ar_rand show
a signiﬁcantly higher power than the reference model summary.
Figure 11: Interaction plot of residual variance and sample size for ExcLow and β = 0.5
For (σ2 = 1;σ2R = 0;n = 25, 50, 100), (σ
2 = 1;σ2R = 0.01;n = 25, 50, 100) and
(σ2 = 1;σ2R = 0.4;n = 100) the power is equal to or slightly lower than 1 for all
methods. For example, for (σ2 = 1;σ2R = 0.01;n = 25) the power only ranges from 0.999
to 0.995 except for summary (0.913).
For (σ2 = 1; σ2R = 0.4;n = 25, 50), lmm_exc shows the highest power. Further-
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more, lmm_exc_rand, lmm_ind_rand, lmm_uns, lmm_uns_rand, lmm_ar_rand show
a large power. The model summary shows the second lowest power and gee_uns by far
the lowest power.
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Figure 12: Power for ExcLow and β = 0.5
For σ2 = 9, summary has the lowest power for the 6 settings with n = 50 and n = 100.
For n = 25 it has the third lowest power and only lmm_ar and lmm_ind are worse.
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For (σ2 = 25; σ2R = 0, 0.01, 0.4;n = 100) summary shows the lowest power. For n = 25
the ﬁfth lowest and for n = 50 the forth lowest power.
For σ2 = 9 and σ2 = 25 lmm_ind, lmm_ind_rand, lmm_ar and lmm_ar_rand are
among the ﬁve methods with the lowest power except for (σ2 = 9;σ2R = 0, 0.01, 0.4;n =
100) where rmANOVA has a lower power than lmm_ind_rand. In the remaining cases
rmANOVA has the sixth lowest power.
For (σ2 = 9, 25;σ2R = 0, 0.01) the models gee_uns, gee_ind and gee_exc perform best
in the case of n = 25 and n = 50. If n = 100 lmm_exc, lmm_exc_rand, lmm_uns and
lmm_uns_rand also perform comparably well.
For (σ2 = 9;σ2R = 0.4;n = 25, 50) lmm_exc and lmm_uns have the highest power
followed by gee_uns, lmm_uns_rand, gee_ind and gee_exc. If (σ2 = 9;σ2R = 0.4;n =
100) lmm_exc, lmm_exc_rand, lmm_uns_rand and lmm_uns perform best followed
by the GEE models.
If we increase the variance σ2, i.e. (σ2 = 25;σ2R = 0.4) the GEE models perform
comparably better. For n = 25 gee_uns has the highest power followed by lmm_uns,
gee_ind and gee_exc. If n = 50 it is gee_ind followed by gee_exc, lmm_exc and
lmm_uns. For n = 100 it is lmm_exc followed by lmm_uns, gee_ind and gee_exc.
Table 10 shows the mean power for each method stratiﬁed by the random slope variance
σ2R.
σ2R = 0, 0.01 σ
2
R = 0.4
Method Power Method Power
gee_uns 0.693 lmm_exc 0.670
gee_exc 0.691 lmm_uns 0.660
gee_ind 0.691 gee_exc 0.656
lmm_uns 0.689 gee_ind 0.656
lmm_uns_rand 0.688 lmm_uns_rand 0.656
lmm_exc 0.683 lmm_exc_rand 0.652
gee_ar 0.683 gee_ar 0.644
lmm_exc_rand 0.678 rmANOVA 0.573
rmANOVA 0.599 lmm_ind_rand 0.559
lmm_ind_rand 0.576 gee_uns 0.555
lmm_ar_rand 0.557 lmm_ar_rand 0.539
lmm_ar 0.550 lmm_ar 0.527
lmm_ind 0.548 lmm_ind 0.525
summary 0.508 summary 0.472
Table 10: Mean power for each method for β = 0.5 and ExcLow stratiﬁed by σ2R
In summary, gee_uns, gee_ind and gee_exc perform best closely followed by lmm_uns
and lmm_uns_rand if there is no or a low random slope eﬀect and a small or medium
sample size. With a high sample size lmm_uns, lmm_uns_rand and lmm_exc are on
the same level as the three GEE models. With a high random slope eﬀect lmm_exc
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peforms best. The model summary shows the lowest power. If there is a high random
slope eﬀect the linear mixed models usually perform better than the GEE models. How-
ever, the higher the residual variance and the lower the sample size, the more the GEE
models can compensate that eﬀect. With β = 1 the power is globally higher but the
results concerning the comparison of the diﬀerent models are the same as with β = 0.5.
The mean power increases with the magnitude of the correlation, from 0.543 (Ind) over
0.619 (ExcLow) and 0.684 (ExcMed) to 0.806 (ExcHigh). Table 11 and 12 show the mean
power for each method stratiﬁed by σ2R for ExcMed and ExcHigh correlation, respectively.
σ2R = 0, 0.01 σ
2
R = 0.4
Method Power Method Power
gee_exc 0.783 lmm_exc 0.752
gee_ind 0.783 lmm_uns 0.736
lmm_uns 0.781 gee_exc 0.734
lmm_uns_rand 0.780 gee_ind 0.734
gee_uns 0.777 lmm_uns_rand 0.731
lmm_exc 0.776 lmm_exc_rand 0.730
lmm_exc_rand 0.769 gee_ar 0.722
gee_ar 0.769 rmANOVA 0.665
rmANOVA 0.694 lmm_ar 0.574
summary 0.592 lmm_ar_rand 0.568
lmm_ar 0.590 lmm_ind_rand 0.565
lmm_ar_rand 0.589 summary 0.549
lmm_ind_rand 0.581 gee_uns 0.538
lmm_ind 0.536 lmm_ind 0.516
Table 11: Mean power for each method for β = 0.5 and ExcMed stratiﬁed by σ2R
For no or low random slope eﬀect the ﬁve best methods remain the same, although
gee_exc and gee_ind have the highest power for ExcMed and ExcHigh and no longer
gee_uns. Also the ﬁve methods with the lowest power remain the same but summary
is only the ﬁfth worst model with ExcMed and ExcHigh. The methods lmm_exc and
lmm_exc_rand improve in the ranking the higher the correlation.
If σ2R = 0.4 the order of the eight methods with the highest power is the same for ExcLow,
ExcMed and ExcHigh. Only the order of the other six methods changes, with the eﬀect
that summary improves the higher the correlation.
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σ2R = 0, 0.01 σ
2
R = 0.4
Method Power Method Power
gee_exc 0.920 lmm_exc 0.887
gee_ind 0.920 lmm_uns 0.865
lmm_uns 0.919 gee_exc 0.864
lmm_exc 0.916 gee_ind 0.864
lmm_uns_rand 0.914 lmm_uns_rand 0.863
lmm_exc_rand 0.911 lmm_exc_rand 0.862
gee_ar 0.908 gee_ar 0.852
gee_uns 0.893 rmANOVA 0.821
rmANOVA 0.862 gee_uns 0.765
summary 0.755 lmm_ar 0.721
lmm_ar 0.741 lmm_ar_rand 0.716
lmm_ar_rand 0.741 summary 0.712
lmm_ind_rand 0.581 lmm_ind_rand 0.561
lmm_ind 0.514 lmm_ind 0.498
Table 12: Mean power for each method for β = 0.5 and ExcHigh stratiﬁed by σ2R
Figure 13 shows the results for β = 0, i.e. no eﬀect. In this case the primary performance
measure is the Type I Error.
The mean error signiﬁcantly decreases with the sample size (βˆn = −0.0001; −0.0002 to
−0.0001) from 0.048 (n = 25) over 0.045 (n = 50) to 0.039 (n = 100). It decreases with
the residual variance from 0.050 (σ2 = 1) over 0.041 (σ2 = 9) to 0.042 (σ2 = 25), but
this trend is not statistically signiﬁcant. It signiﬁcantly increases with the random slope
variance (βˆσ2R = 0.0484; 0.0343 to 0.0625) from 0.041 (σ
2
R = 0) over 0.041 (σ
2
R = 0.01)
to 0.050 (σ2R = 0.4). Also, there is a signiﬁcant interaction between residual variance
and random slope variance (βˆσ2∗σ2R = −0.0022; −0.0027 to −0.0016) because the power
increases more rapidly with the random slope variance for σ2 = 1 than for σ2 = 9, 25.
There is no signiﬁcant interaction between residual variance or random slope variance
and sample size. The models lmm_ind, lmm_ind_rand, lmm_ar and lmm_ar_rand
have a signiﬁcantly lower Type I Error than the reference model summary. Of the
remaining models, only rmANOVA and lmm_exc_rand do not show a signiﬁcantly
higher Type I Error than summary.
Table 13 shows the mean error for each method stratiﬁed by σ2R. The methods with the
lowest power summary, lmm_ind_rand, lmm_ind, lmm_ar_rand and lmm_ar also
have the lowest Type I Error.
For no or a low random slope eﬀect the models with the highest power also have the higest
error, whereas gee_exc and gee_ind which have a higher power than lmm_uns and
lmm_uns_rand have a slightly lower error than the two linear mixed models assuming
an unstructured correlation matrix.
For σ2R = 0.4 the model with the highest power lmm_exc also has by far the highest
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Type I Error. The models gee_uns and lmm_exc_rand have a medium power but a
comparably high error.
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Figure 13: Type I Error for ExcLow and β = 0
With ExcMed the models with the highest power gee_exc and gee_ind for σ2R = 0, 0.01
have the ﬁfth (0.053) and sixth highest error (0.053). The three best models after the two
aforementioned show a higher error. For σ2R = 0.4 the models lmm_exc and lmm_uns
with the highest power also have the highest error (0.096 and 0.066). However, gee_exc
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(0.058) and gee_ind (0.058) only have a median error. Only gee_ar and the ﬁve methods
with the lowest power have a smaller error.
With ExcHigh and σ2R = 0, 0.01 the models with the highest power gee_exc (0.055) and
gee_ind (0.055) have a lower error than gee_uns (0.059), gee_ar (0.057) and lmm_uns
(0.056). For σ2R = 0.4 the models lmm_exc and lmm_uns with the highest power also
have the highest error (0.121 and 0.064). However, gee_exc (0.054) and gee_ind (0.054)
only have a median error. Only gee_ind and the ﬁve methods with the lowest power
have a smaller error.
σ2R = 0, 0.01 σ
2
R = 0.4
Method Type I Error Method Type I Error
gee_uns 0.059 lmm_exc 0.085
lmm_uns 0.057 lmm_uns 0.062
lmm_uns_rand 0.056 gee_uns 0.060
gee_exc 0.056 lmm_exc_rand 0.060
gee_ind 0.056 lmm_uns_rand 0.056
gee_ar 0.055 gee_ar 0.055
lmm_exc 0.050 rmANOVA 0.055
rmANOVA 0.049 gee_exc 0.055
lmm_exc_rand 0.047 gee_ind 0.055
summary 0.047 summary 0.052
lmm_ind_rand 0.013 lmm_ind_rand 0.032
lmm_ar_rand 0.011 lmm_ar_rand 0.027
lmm_ar 0.010 lmm_ar 0.027
lmm_ind 0.008 lmm_ind 0.021
Table 13: Mean Type I Error for each method for β = 0 and ExcLow stratiﬁed by σ2R
Auto-regressive correlation
In this paragraph the results for the simulated data with auto-regressive correlation be-
tween the repeated measures are presented. Figure 14 shows the results for β = 0.5
and ArLow. The strength of the power in this heat map is represented as colors from
white to steelblue whereas white stands for low and steelblue for high power. The plot
contains nine matrices, one for each σ2-σ2R combination. The sample size is plotted on
the horizontal axis and the method on the vertical axis. Therefore all simulation results
for β = 0.5 and ArLow are shown in this plot.
The mean power signiﬁcantly increases with the sample size (βˆn = 0.0026; 95%-CI:
0.0018 to 0.0034) from 0.441 (n = 25) over 0.546 (n = 50) to 0.688 (n = 100). On the
other hand it signiﬁcantly decreases with the residual variance (βˆσ2 = −0.0313; −0.0345
to −0.0282) from 0.963 (σ2 = 1) over 0.478 (σ2 = 9) to 0.234 (σ2 = 25) and the random
slope variance (βˆσ2 = −0.2467; −0.4306 to −0.0628) from 0.579 (σ2R = 0) over 0.567
(σ2R = 0.01) to 0.529 (σ
2
R = 0.4). There are no signiﬁcant interactions between the
simulation parameters. All models show a signiﬁcantly higher power than the reference
43
model summary.
For (σ2 = 1;σ2R = 0;n = 25, 50, 100), (σ
2 = 1;σ2R = 0.01;n = 25, 50, 100) and
(σ2 = 1;σ2R = 0.4;n = 100) the power is equal to or slightly lower than 1 for all
methods. For example, for (σ2 = 1;σ2R = 0.01;n = 25) the power only ranges from 0.987
to 0.970 except for rmANOVA (0.949) and summary (0.824).
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Figure 14: Power for ArLow and β = 0.5
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For (σ2 = 1;σ2R = 0.4;n = 25, 50), lmm_exc shows the highest power followed by
lmm_exc_rand, lmm_ind_rand, lmm_ar and lmm_ar_rand. The four GEE models
and summary have the lowest power, whereas summary shows the second lowest power
and gee_uns by far the lowest power.
For σ2 = 9 and σ2 = 25, summary has the lowest and rmANOVA the second lowest
power for all 18 settings. Therefore rmANOVA performs better if the repeated measures
follow an exchangeable correlation structure than an auto-regressive correlation struc-
ture.
Compared to the exchangeable correlation structure, lmm_ind, lmm_ind_rand, lmm_ar
and lmm_ar_rand perform better and are among the methods with the highest power
for some settings.
However, lmm_exc and lmm_exc_rand perform best for all 18 settings with σ2 = 9 and
σ2 = 25. In the case of σ2R = 0 or σ
2
R = 0.01 lmm_ind_rand, gee_uns and gee_ar also
perform well.
If σ2R = 0.4, the GEE models improve compared to the linear mixed models the higher
the residual variance or the lower the sample size. For example, for (σ2 = 9;σ2R =
0.4;n = 100) the four GEE models, rmANOVA and summary have the lowest power.
If we decrease the sample size to n = 25, i.e. (σ2 = 9; σ2R = 0.4;n = 25), gee_uns and
gee_ar have the forth and sixth highest power and gee_exc and gee_ind are better than
lmm_ar, lmm_ar_rand and lmm_ind.
Table 14 shows the mean power for each method stratiﬁed by the random slope variance
σ2R.
σ2R = 0, 0.01 σ
2
R = 0.4
Method Power Method Power
lmm_exc 0.643 lmm_exc 0.670
lmm_exc_rand 0.633 lmm_exc_rand 0.660
lmm_ind_rand 0.587 lmm_ind_rand 0.656
gee_uns 0.578 lmm_ar 0.656
gee_ar 0.574 lmm_ar_rand 0.656
lmm_uns 0.574 lmm_ind 0.652
lmm_uns_rand 0.572 lmm_uns 0.644
gee_exc 0.571 lmm_uns_rand 0.573
gee_ind 0.571 gee_ar 0.559
lmm_ind 0.570 gee_exc 0.555
lmm_ar_rand 0.568 gee_ind 0.539
lmm_ar 0.568 rmANOVA 0.527
rmANOVA 0.548 summary 0.525
summary 0.461 gee_uns 0.472
Table 14: Mean power for each method for β = 0.5 and ArLow stratiﬁed by σ2R
In summary, lmm_exc, lmm_exc_rand and lmm_ind_rand perform best if the re-
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peated measures follow an auto-regressive low correlation. In case of no or a low random
slope eﬀect gee_uns and gee_ar have the highest power after the three aforementioned
methods. However, gee_uns is the worst method if there is a high random slope eﬀect.
In that case, lmm_ar and lmm_ar_rand have the forth and ﬁfth highest power. The
models rmANOVA and summary do not perform well in any case. If there is a high
random slope eﬀect the linear mixed models usually perform better than the GEE mod-
els. However, the higher the residual variance and the lower the sample size, the more
the GEE models can compensate that eﬀect. With β = 1 the power is globally higher
but the results concerning the comparison of the diﬀerent models are the same as with
β = 0.5.
The mean power increases with the magnitude of the correlation, from 0.558 (ArLow)
over 0.595 (ArMed) to 0.698 (ArHigh). Table 15 and 16 show the mean power for each
method stratiﬁed by σ2R for ArMed and ArHigh, respectively.
σ2R = 0, 0.01 σ
2
R = 0.4
Method Power Method Power
lmm_exc 0.702 lmm_exc 0.670
lmm_exc_rand 0.682 lmm_exc_rand 0.660
gee_ar 0.616 lmm_ar 0.656
gee_uns 0.615 lmm_ar_rand 0.656
lmm_uns 0.615 lmm_uns 0.656
lmm_uns_rand 0.612 rmANOVA 0.652
gee_exc 0.611 gee_ar 0.644
gee_ind 0.611 lmm_uns_rand 0.573
lmm_ar 0.610 lmm_ind_rand 0.559
lmm_ar_rand 0.607 gee_exc 0.555
rmANOVA 0.605 gee_ind 0.539
lmm_ind_rand 0.595 lmm_ind 0.527
lmm_ind 0.564 summary 0.525
summary 0.522 gee_uns 0.472
Table 15: Mean power for each method for β = 0.5 and ArMed stratiﬁed by σ2R
The models lmm_exc and lmm_exc_rand also have the highest power for ArMed and
ArHigh. The higher the magnitude of the auto-regressive correlation is, the better
rmANOVA performs. For σ2R = 0, 0.01 and ArHigh, rmANOVA has the third highest
power. The linear mixed models lmm_ind_rand (third highest power for σ2R = 0, 0.01
and ArLow) and lmm_ind peform poorly in case of ArMed and even have the lowest
power in case of ArHigh.
In case of σ2R = 0.4, the remaining linear mixed models usually perform better than the
GEE models no matter the magnitude of the correlation.
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σ2R = 0, 0.01 σ
2
R = 0.4
Method Power Method Power
lmm_exc 0.831 lmm_exc 0.808
lmm_exc_rand 0.769 lmm_exc_rand 0.725
rmANOVA 0.741 lmm_ar 0.714
gee_ar 0.738 rmANOVA 0.709
lmm_uns 0.738 lmm_uns 0.697
gee_exc 0.734 lmm_ar_rand 0.696
gee_ind 0.734 gee_ar 0.696
lmm_ar 0.733 gee_exc 0.689
lmm_ar_rand 0.726 gee_ind 0.689
lmm_uns_rand 0.720 lmm_uns_rand 0.680
gee_uns 0.699 summary 0.606
summary 0.652 gee_uns 0.599
lmm_ind_rand 0.598 lmm_ind_rand 0.575
lmm_ind 0.543 lmm_ind 0.514
Table 16: Mean power for each method for β = 0.5 and ArHigh stratiﬁed by σ2R
Figure 15 shows the results for ArLow and β = 0, i.e. no eﬀect. In this case the primary
performance measure is the Type I Error.
The error is higher for n = 50 (0.069) than for n = 25 (0.063) and n = 100 (0.062). It
decreases with the residual variance from 0.069 (σ2 = 1) over 0.063 (σ2 = 9) to 0.063
(σ2 = 25). However, there is no statistically signiﬁcant eﬀect for sample size and residual
variance. The Type I Error signiﬁcantly increases with the random slope variance (βˆσ2R =
0.0396; 0.0281 to 0.0510) from 0.063 (σ2R = 0) over 0.062 (σ
2
R = 0.01) to 0.069 (σ
2
R = 0.4).
These observations hold for ArMed and ArHigh. Also, there is a signiﬁcant interaction
between residual variance and random slope variance (βˆσ2∗σ2R = −0.0016; −0.0021 to−0.0011) because the power increases more rapidly with the random slope variance for
σ2 = 1 than for σ2 = 9, 25. There is no signiﬁcant interaction between residual variance
or random slope variance and sample size. All models have a signiﬁcantly higher Type
I Error than the reference model summary.
The method summary has the lowest Type I Error in 19 and a Type I Error lower than
0.05 in 18 of the 27 settings. Although rmANOVA has the second-lowest power it has a
Type I Error above the median in 8 and above the third quartile in 16 of the 27 settings.
Usually these comparably high errors result from a high random slope eﬀect or a low
sample size.
In general, the methods with the highest power also have the highest errors and the
models with a low power show a low error for ArLow, ArMed and ArHigh. The only
nameable deviation from this rule is that lmm_exc_rand, the model with the second
highest power, only shows the forth highest error for σ2R = 0.4 and ArHigh.
47
Rand. Var. 0, Res. Var. 1 Rand. Var. 0, Res. Var. 9 Rand. Var. 0, Res. Var. 25
Rand. Var. 0.01, Res. Var. 1 Rand. Var. 0.01, Res. Var. 9 Rand. Var. 0.01, Res. Var. 25
Rand. Var. 0.4, Res. Var. 1 Rand. Var. 0.4, Res. Var. 9 Rand. Var. 0.4, Res. Var. 25
summary
rmANOVA
gee_ind
gee_exc
gee_ar
gee_uns
lmm_ind
lmm_exc
lmm_ar
lmm_uns
lmm_ind_rand
lmm_exc_rand
lmm_ar_rand
lmm_uns_rand
summary
rmANOVA
gee_ind
gee_exc
gee_ar
gee_uns
lmm_ind
lmm_exc
lmm_ar
lmm_uns
lmm_ind_rand
lmm_exc_rand
lmm_ar_rand
lmm_uns_rand
summary
rmANOVA
gee_ind
gee_exc
gee_ar
gee_uns
lmm_ind
lmm_exc
lmm_ar
lmm_uns
lmm_ind_rand
lmm_exc_rand
lmm_ar_rand
lmm_uns_rand
25 50 100 25 50 100 25 50 100
Sample Size
M
et
ho
d
0.050
0.075
0.100
0.125
0.150
0.175
Power/Type I Error
Figure 15: Type I Error for ArLow and β = 0
Unstructured correlation
In this paragraph the results for the simulated data with unstructured correlation matrix
for the repeated measures are presented. Figure 16 shows the results for Uns and
β = 0.5. The strength of the power in this heat map is represented as colors from
white to steelblue. The plot contains nine matrices, one for each σ2-σ2R combination.
The sample size is plotted on the horizontal axis and the method on the vertical axis.
Therefore all simulation results for β = 0.5 and Uns are shown in this plot.
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Figure 16: Power for Uns and β = 0.5
The mean power signiﬁcantly increases with the sample size (βˆn = 0.0024; 95%-CI:
0.0017 to 0.0031) from 0.488 (n = 25) over 0.627 (n = 50) to 0.785 (n = 100). On the
other hand it signiﬁcantly decreases with the residual variance (βˆσ2 = −0.0339; −0.0367
to −0.0311) from 0.972 (σ2 = 1) over 0.617 (σ2 = 9) to 0.311 (σ2 = 25) and the random
slope variance (βˆσ2 = −0.2450; −0.4079 to −0.0822) from 0.653 (σ2R = 0) over 0.645
(σ2R = 0.01) to 0.601 (σ
2
R = 0.4). Also, there is a signiﬁcant interaction between residual
variance and sample size (βˆσ2∗n = 0.0001; 0.0001 to 0.0002) because the power increases
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more rapidly with the sample size for σ2 = 9, 25 than for σ2 = 1. There is no signiﬁcant
interaction between residual variance or sample size and random slope variance. All
models except for gee_uns, lmm_ind, lmm_ar and lmm_ar_rand show a signiﬁcantly
higher power than the reference model summary.
For (σ2 = 1;σ2R = 0;n = 25, 50, 100) and (σ
2 = 1;σ2R = 0.01;n = 25, 50, 100) the power
is equal to or slightly lower than 1 for all methods. For example, for (σ2 = 1;σ2R =
0.01;n = 25) the power only ranges from 0.999 to 0.993 apart from summary (0.959).
For (σ2 = 1;σ2R = 0.4;n = 25, 50), lmm_exc shows the highest power. Furthermore,
lmm_exc_rand, lmm_ar, lmm_uns and lmm_ind_rand show a large power. The mod-
els lmm_ind, summary and gee_uns have the lowest power. For (σ2 = 1;σ2R = 0.4;n =
100) all models have a power of 1 except for gee_uns which only has a power of 0.395.
If we increase the variance σ2, i.e. (σ2 = 9;σ2R = 0.4;n = 25, 50, 100) the GEE models
perform better. Now, gee_uns has power above the median. The methods lmm_exc,
lmm_exc_rand, lmm_uns and lmm_uns_rand still perform best but lmm_ind, lmm_ar,
lmm_ar_rand, lmm_ind_rand and summary have the lowest power. For (σ2 = 25;σ2R =
0.4;n = 25, 50, 100) lmm_exc and lmm_exc_rand are still the methods with the highest
power. However, for n = 25 and n = 100 gee_uns, gee_exc and gee_ind are now the
best models after the aforementioned. For n = 50 lmm_uns and lmm_uns_rand are
still better than the three GEE models.
For (σ2 = 9; σ2R = 0, 0.01;n = 25, 50, 100), lmm_exc and lmm_exc_rand have the
highest power, usually followed by gee_uns, lmm_uns and lmm_uns_rand. Again,
lmm_ind, lmm_ind_rand, lmm_ar, lmm_ar_rand and summary have the lowest power.
σ2R = 0, 0.01 σ
2
R = 0.4
Method Type I Error Method Type I Error
lmm_exc 0.061 lmm_exc 0.075
lmm_exc_rand 0.057 lmm_exc_rand 0.072
lmm_uns 0.057 lmm_uns 0.066
gee_uns 0.057 lmm_uns_rand 0.066
lmm_uns_rand 0.056 gee_exc 0.064
gee_exc 0.056 gee_ind 0.060
gee_ind 0.055 gee_ar 0.058
gee_ar 0.054 rmANOVA 0.057
rmANOVA 0.054 lmm_ar 0.055
lmm_ar 0.053 lmm_ar_rand 0.055
lmm_ar_rand 0.053 lmm_ind_rand 0.055
lmm_ind_rand 0.052 lmm_ind 0.054
summary 0.047 summary 0.045
lmm_ind 0.046 gee_uns 0.045
Table 17: Mean power for each method for β = 0.5 and Uns stratiﬁed by σ2R
If we further increase the variance to σ2 = 25 these results are conﬁrmed. However,
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gee_ind and gee_exc show a higher power than lmm_uns and lmm_uns_rand for
(σ2 = 25;σ2R = 0;n = 100) and (σ
2 = 25;σ2R = 0.01;n = 25, 100).
Table 17 shows the mean power for each method stratiﬁed by σ2R.
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Figure 17: Type I Error for Uns and β = 0
In summary, lmm_ind, summary, lmm_ind_rand, lmm_ar_rand and lmm_ar peform
poorly if the repeated measurements follow an unstructured correlation matrix. With
a high random slope eﬀect gee_uns is the worst method, but for σ2R = 0, 0.01 it has
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the forth highest power. Apart from that lmm_exc, lmm_exc_rand, lmm_uns and
lmm_uns_rand perform very well. In case of a high random slope variance the GEE
models improve with increasing residual variance. With β = 1 the power is globally
higher but the results concerning the comparison of the diﬀerent models are the same
as with β = 0.5.
Figure 17 shows the results for β = 0, i.e. no eﬀect. In this case the primary performance
measure is the Type I Error.
The error decreases with the sample size from 0.055 (n = 25) over 0.054 (n = 50) to
0.049 (n = 100) and the residual variance from 0.058 (σ2 = 1) over 0.050 (σ2 = 9)
to 0.050 (σ2 = 25), but these trends are not statistically signiﬁcant. It signiﬁcantly
increases with the random slope variance (βˆσ2R = 0.0622; 0.0471 to 0.0773) from 0.048
(σ2R = 0) over 0.050 (σ
2
R = 0.01) to 0.060 (σ
2
R = 0.4). Also, there is a signiﬁcant
interaction between residual variance and random slope variance (βˆσ2∗σ2R = −0.0021;−0.0028 to −0.0015) because the power increases more rapidly with the random slope
variance for σ2 = 1 than for σ2 = 9, 25. There is no signiﬁcant interaction between
residual variance or random slope variance and sample size. The models lmm_ind,
lmm_ind_rand, lmm_ar and lmm_ar_rand have a signiﬁcantly lower Type I Error
than the reference model summary. Of the remaining models, only gee_ar does not
show a signiﬁcantly higher Type I Error than summary.
The models with a high power also have a high error and vice versa. The only exception
of this rule, is that gee_uns has the ﬁfth highest error if σ2R = 0.4 although it has the
lowest power.
The models summary, lmm_ar, lmm_ar_rand, lmm_ind and lmm_ind_rand have the
lowest errors and lmm_exc and lmm_exc_rand the highest errors.
3.4.2. Secondary performance measure: Coverage
In this chapter the results for the secondary performance measures coverage of the 95%
conﬁdence interval around the true eﬀect will be described. It is not possible to compute
the conﬁdence interval for rmANOVA because this method does not provide an estimate
of the eﬀect size.
Independent correlation
For the simulated data with no correlation between the repeated measures, the mean
coverage of the 95% conﬁdence interval around the true eﬀect over all n, σ2 and σ2R is
almost the same for β = 0 (0.943), β = 0.5 (0.943) and β = 1 (0.943). Also, the diﬀerent
characteristics of the models are the same. Therefore only the results for β = 0 will be
presented here.
Figure 18 shows the results for Ind and β = 0. The level of coverage in this heat map is
represented as colors from white to steelblue whereas white means low and steelblue high
coverage. The plot contains nine matrices, one for each σ2-σ2R combination. The sample
size is plotted on the horizontal axis and the method on the vertical axis. Therefore all
simulation results for β = 0 and Ind are shown in this plot.
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Figure 18: Coverage of 95%-CI around true eﬀect for Ind and β = 0
The mean coverage signiﬁcantly increases with the sample size (βˆn = 0.0001; 0.0001 to
0.0002) from 0.937 (n = 25) over 0.942 (n = 50) to 0.949 (n = 100). On the other hand
it signiﬁcantly decreases with the random slope variance (βˆσ2R = −0.0379; −0.0493 to
−0.0265) from 0.946 (σ2R = 0) over 0.942 (σ2R = 0.01) to 0.939 (σ2R = 0.4). The mean
coverage for σ2 = 1 is lower (0.940) than for σ2 = 9 (0.944) and σ2 = 25 (0.944) but there
is no statistically signiﬁcant eﬀect. There is no signiﬁcant interaction between residual
variance and sample size. However, there is a signiﬁcant interaction between residual
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variance and random slope variance (βˆσ2∗σ2R = 0.0009; 0.0004 to 0.0014) because the
mean coverage decreases more rapidly with the random slope variance if σ2 = 1 than if
σ2 = 9, 25 and sample size and random slope variance (βˆn∗σ2R = 0.0002; 0.0001 to 0.0004)
because the mean coverage decreases with the random slope variance if n = 25, 50 but
is highest for σ2R = 0.01 if n = 100. All models have a signiﬁcantly lower coverage than
the reference model summary.
For (σ2 = 1;σ2R = 0;n = 25) lmm_ar (0.958) and lmm_ar_rand (0.955) have the
higest coverage but the lowest for (σ2 = 1;σ2R = 0;n = 50) (0.940 and 0.940) and (σ
2 =
1;σ2R = 0;n = 100) (0.945 and 0.943). In general, there is no clear trend visible because
all methods have a high coverage close to 1. For example, for (σ2 = 1;σ2R = 0;n = 100)
the coverage ranges from 0.952 for lmm_uns to 0.943 for lmm_ar_rand.
For (σ2 = 1;σ2R = 0.01;n = 25, 50, 100) summary has the highest coverage ratio al-
though it has the lowest power as described in chapter 3.4.1. These results all hold for
σ2 = 9 and σ2 = 25.
For (σ2 = 1;σ2R = 0.4;n = 25, 50, 100) gee_ar, gee_exc, gee_ind and summary have
the higest and lmm_exc, lmm_uns, lmm_ind_rand and lmm_ar_rand have the lowest
coverage although the linear mixed models perform better than the GEE models con-
cerning power with a low residual variance and a high random slope variance.
If the residual variance is increased, i.e. (σ2 = 9; σ2R = 0.4), gee_ar, gee_exc, gee_ind
and summary only have the highest coverage for n = 100. If n = 50 the four models
are still among the ﬁve with the highest coverage but lmm_ar has the second highest
coverage. For n = 25 summary, lmm_ind, lmm_ar, lmm_exc_rand, lmm_ind_rand
and lmm_ar_rand have the highest coverage.
For (σ2 = 25;σ2R = 0.4) summary and four linear mixed models are amongst the meth-
ods with the highest coverage, except for n = 50, where gee_ar has the forth highest
coverage.
Therefore, if there is a high random slope eﬀect, the coverage for the GEE models de-
creases with increasing residual variance and decreasing sample size compared to the
linear mixed models. This is the exact reversed eﬀect we observed with the primary
outcome power.
Exchangeable correlation
For the simulated data with low exchangeable correlation structure for the repeated
measures, the mean coverage of the 95% conﬁdence interval around the true eﬀect over
all n, σ2 and σ2R is almost the same for β = 0 (0.956), β = 0.5 (0.956) and β = 1 (0.956).
Also, the diﬀerent characteristics of the models are the same. Therefore only the results
for β = 0.5 will be presented here.
Figure 19 shows the results for ExcLow and β = 0.5. The level of coverage in this
heat map is represented as colors from white to steelblue whereas white means low and
steelblue high coverage. The plot contains nine matrices, one for each σ2-σ2R combination.
The sample size is plotted on the horizontal axis and the method on the vertical axis.
Therefore all simulation results for β = 0.5 and ExcLow are shown in this plot.
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Figure 19: Coverage of 95%-CI around true eﬀect for ExcLow and β = 0.5
The mean coverage signiﬁcantly increases with the sample size (βˆn = 0.0001; 0.0001 to
0.0002) from 0.951 (n = 25) over 0.955 (n = 50) to 0.961 (n = 100). The mean coverage
for σ2 = 1 is lower (0.950) than for σ2 = 9 (0.960) and σ2 = 25 (0.958) and there is
no signiﬁcant eﬀect. On the other hand, the coverage signiﬁcantly decreases with the
random slope variance (βˆσ2R = −0.0514; −0.0667 to −0.0362) from 0.959 (σ2R = 0) over
0.959 (σ2R = 0.01) to 0.949 (σ
2
R = 0.4). These results also hold for ExcMed and ExcHigh.
There is no signiﬁcant interaction between residual variance or random slope variance
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and sample size. However, there is a signiﬁcant interaction between residual variance and
random slope variance (βˆσ2∗σ2R = 0.0024; 0.0017 to 0.0030) because the mean coverage
decreases more rapidly with the random slope variance if σ2 = 1 than if σ2 = 9, 25. The
models gee_uns, lmm_exc and lmm_uns have a signiﬁcantly lower coverage than the
reference model summary and lmm_ind, lmm_ar, lmm_ind_rand and lmm_ar_rand
have a signiﬁcantly higher coverage.
For (σ2 = 1;σ2R = 0, 0.01;n = 25, 50, 100), lmm_ind, lmm_ar, lmm_ar_rand and
lmm_ind_rand have the highest coverage and gee_uns, gee_ind and gee_exc have a
coverage equal to or lower than the median of all methods. This also holds for σ2 = 9
and σ2 = 25 and ExcMed and ExcHigh. The three mentioned GEE models have the
highest power for σ2R = 0, 0.01 and the four linear mixed models and summary the lowest
power in these settings.
For (σ2 = 1;σ2R = 0.4) lmm_exc, lmm_exc_rand and lmm_uns have the lowest cov-
erage. For n = 25 lmm_ind, lmm_ar, summary and lmm_ar_rand have the highest
coverage. If n = 50, 100 it is lmm_ind, gee_ar, summary, gee_exc and gee_ind.
For (σ2 = 9;σ2R = 0.4) and (σ
2 = 25;σ2R = 0.4) lmm_ind, lmm_ar, lmm_ar_rand and
lmm_ind_rand have the higest coverage. Therefore, the models with a low power have
a high coverage again. These results also count for ExcMed and ExcHigh.
Auto-regressive correlation
For the simulated data with low auto-regressive correlation structure for the repeated
measures, the mean coverage of the 95% conﬁdence interval around the true eﬀect over
all n, σ2 and σ2R is almost the same for β = 0 (0.934), β = 0.5 (0.934) and β = 1 (0.934).
Also, the diﬀerent characteristics of the models are the same. Therefore only the results
for β = 1 will be presented here.
Figure 20 shows the results for ArLow and β = 1. The level of coverage in this heat
map is represented as colors from white to steelblue whereas white means low and steel-
blue high coverage. The plot contains nine matrices, one for each σ2-σ2R combination.
The sample size is plotted on the horizontal axis and the method on the vertical axis.
Therefore all simulation results for β = 1 and ArLow are shown in this plot.
The mean coverage is lower for n = 50 (0.930) than for n = 25 (0.935) and n = 100
(0.937) but there is no signiﬁcant eﬀect. It signiﬁcantly decreases with the random
slope variance (βˆσ2R = −0.0428; −0.0550 to −0.0306) from 0.936 (σ2R = 0) over 0.936
(σ2R = 0.01) to 0.929 (σ
2
R = 0.4). It increases with the residual variance from 0.930
(σ2 = 1) over 0.935 (σ2 = 9) to 0.936 (σ2 = 25), but this trend is not statistically
signiﬁcant. These results also hold for ArMed and ArHigh. There is no signiﬁcant inter-
action between residual variance or random slope variance and sample size. However,
there is a signiﬁcant interaction between residual variance and random slope variance
(βˆσ2∗σ2R = 0.0017; 0.0012 to 0.0022) because the mean coverage decreases more rapidly
with the random slope variance if σ2 = 1 than if σ2 = 9, 25. All models have a signiﬁ-
cantly lower coverage than the reference model summary.
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Figure 20: Coverage of 95%-CI around true eﬀect for ArLow and β = 1
For (σ2 = 1; σ2R = 0, 0.01;n = 25, 50, 100), lmm_exc and lmm_exc_rand have the
lowest coverage rate. For (σ2 = 1;σ2R = 0, 0.01;n = 25), lmm_ar, lmm_ar_rand and
lmm_ind have the highest coverage. For (σ2 = 1;σ2R = 0;n = 50, 100), it is lmm_ar,
lmm_ar_rand and summary and for (σ2 = 1;σ2R = 0.01;n = 50, 100) summary, gee_exc
and gee_ind. As described in the previous chapter, lmm_exc and lmm_exc_rand have
the highest power in these settings and summary, lmm_ar, lmm_ar_rand, lmm_ind,
gee_exc and gee_ind a rather low power. These results also hold for σ2 = 9 and σ2 = 25.
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For ArMed and ArHigh some of these results diﬀer. In the case of ArMed and (σ2 =
1;σ2R = 0, 0.01;n = 25), lmm_ar, lmm_ar_rand lmm_ind and lmm_ind_rand have the
highest coverage. For (σ2 = 1;σ2R = 0;n = 50, 100) and (σ
2 = 1;σ2R = 0.01;n = 50), it is
lmm_ind, summary, lmm_ar, lmm_ar_rand and lmm_ind_rand and for (σ2 = 1;σ2R =
0.01;n = 100) lmm_ind, summary, gee_exc, gee_ind and lmm_ind_rand. Basically,
the diﬀerence to the results with ArLow are that lmm_ind and lmm_ind_rand have a
higher coverage. These two linear mixed models show a low power for ArMed than for
ArLow. These results also hold for σ2 = 9 and σ2 = 25.
For σ2R = 0.4 lmm_exc, lmm_exc_rand and lmm_ind_rand have the lowest coverage.
For (σ2 = 1;σ2R = 0.4) summary, gee_exc, gee_ind and gee_ar have the higest coverage.
For (σ2 = 9;σ2R = 0.4;n = 25) gee_ar, lmm_ar, lmm_ar_rand, gee_exc and gee_ind
have the highest coverage. For n = 50 and n = 100, it is summary, gee_exc and
gee_ind.
For (σ2 = 25;σ2R = 0.4;n = 25, 50) lmm_ar, lmm_ar_rand, lmm_ind, gee_ar and
summary have the highest coverage. For n = 100 it is summary, gee_exc, gee_ind,
gee_uns and lmm_ind.
In summary, for σ2R = 0.4 the GEE models usually have a high coverage. However,
with an increasing residual variance and decreasing sample size the linear mixed models
improve compared to the GEE models. This is the reversed eﬀect described in chapter
3.4.1 for the power.
These results diﬀer for ArMed. For (σ2 = 1;σ2R = 0.4) lmm_exc, lmm_exc_rand,
lmm_ar, lmm_ar_rand, lmm_ind_rand and lmm_uns have the lowest coverage and
the GEE models and summary a rather high coverage rate.
For σ2 = 9 and σ2 = 25 lmm_exc and lmm_exc_rand have the lowest coverage. Again,
the linear mixed models improve compared to the GEE models with increasing residual
variance and decreasing sample size. For example, for (σ2 = 25;σ2R = 0.4;n = 25)
lmm_ind, lmm_ind_rand, lmm_ar_rand and lmm_ar have the highest coverage and
for (σ2 = 9;σ2R = 0.4;n = 100) lmm_ind, summary, gee_exc and gee_ind. These
results are very similar for ArHigh. The main diﬀerence is that lmm_ind has the highest
coverage for all 9 settings and lmm_ind_rand the second highest coverage for for the 6
settings with σ2 = 9 and σ2 = 25. The two linear models with independent correlation
structure have the lowest power in case of σ2R = 0.4 and ArHigh.
Unstructured correlation
For the simulated data with unstructured correlation between the repeated measures,
the mean coverage of the 95% conﬁdence interval around the true eﬀect over all n, σ2 and
σ2R is the same for β = 0, β = 0.5 and β = 1 (0.947). Also, the diﬀerent characteristics
of the models are the same. Therefore only the results for β = 1 will be presented here.
Figure 21 shows the results for Uns and β = 1. The level of coverage in this heat map is
represented as colors from white to steelblue whereas white means low and steelblue high
coverage. The plot contains nine matrices, one for each σ2-σ2R combination. The sample
size is plotted on the horizontal axis and the method on the vertical axis. Therefore all
simulation results for β = 1 and Uns are shown in this plot.
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Figure 21: Coverage of 95%-CI around true eﬀect for Uns and β = 1
The mean coverage increases with the sample size from 0.944 (n = 25) over 0.946
(n = 50) to 0.950 (n = 100) but not signiﬁcantly. On the other hand, the coverage
signiﬁcantly decreases with the random slope variance (βˆσ2R = −0.0651; −0.0815 to
−0.0488) from 0.952 (σ2R = 0) over 0.949 (σ2R = 0.01) to 0.939 (σ2R = 0.4). The mean
coverage for σ2 = 1 is lower (0.941) than for σ2 = 9 (0.950) and σ2 = 25 (0.950) but
there is no signiﬁcant eﬀect. There is no signiﬁcant interaction between residual variance
or random slope variance and sample size. However, there is a signiﬁcant interaction
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between residual variance and random slope variance (βˆσ2∗σ2R = 0.0022; 0.0015 to 0.0029)
because the mean coverage decreases more rapidly with the random slope variance if σ2 =
1 than if σ2 = 9, 25. The models gee_uns, lmm_exc, lmm_exc_rand, lmm_uns and
lmm_uns_rand have a signiﬁcantly lower coverage than the reference model summary
and lmm_ind, lmm_ar, lmm_ind_rand and lmm_ar_rand have a signiﬁcantly higher
coverage.
For (σ2 = 1;σ2R = 0, 0.01;n = 25, 50, 100) lmm_ind, lmm_ind_rand, lmm_ar and
lmm_ar_rand have the highest coverage and lmm_exc, lmm_exc_rand and gee_uns
have a low coverage. The ranking with the primary performance measure power is vice
versa. These results also hold for the higher residual variances σ2 = 9 and σ2 = 25.
For (σ2 = 1;σ2R = 0.4) lmm_exc, lmm_exc_rand and lmm_ar have the lowest coverage.
For (σ2 = 9;σ2R = 0.4;n = 50, 100) and (σ
2 = 25;σ2R = 0.4;n = 100) it is lmm_exc,
lmm_exc_rand and lmm_uns and for (σ2 = 9;σ2R = 0.4;n = 25) and (σ
2 = 25;σ2R =
0.4;n = 25, 50) lmm_exc, lmm_exc_rand and gee_uns have a low coverage.
The method lmm_ind has the highest coverage for 8 of the 9 settings with σ2R = 0.4.
For (σ2 = 1; σ2R = 0.4;n = 100) gee_uns has the highest coverage. For σ
2 = 1 all GEE
models have a coverage equal to or above the median coverage of all methods. For σ2 = 9
and σ2 = 25 lmm_ind is followed by lmm_ind_rand, lmm_ar and lmm_ar_rand and
the GEE models have a lower coverage than these four linear mixed models which show
a comparable low power.
Therefore, if there is a high random slope eﬀect, the coverage for the GEE models
decreases with increasing residual variance compared to the linear mixed models. This
is the exact reversed eﬀect we observed with the primary outcome power.
3.4.3. Secondary performance measure: Mean Square Error
In this chapter the results for the secondary performance measure mean square error will
be described. It is not possible to compute this performance measure for rmANOVA as
it does not provide an estimate of the eﬀect size.
As there are some outliers, no linear regression models will be applied to this performance
measure and medians will be presented instead of means.
Independent correlation
For the simulated data with no correlation between the repeated measures, the mean
MSE over all n, σ2 and σ2R is almost the same for β = 0 (0.128), β = 0.5 (0.128) and
β = 1 (0.128). Also, the diﬀerent characteristics of the models are the same. Therefore
only the results for β = 0 will be presented here.
Figure 22 shows the results for Ind and β = 0. The level of MSE in this heat map
is represented as colors from white to steelblue whereas white means low and steelblue
high MSE. As there are some outliers, all heat maps with the MSE are only ranged from
0 to 1. The plot contains nine matrices, one for each σ2-σ2R combination. The sample
size is plotted on the horizontal axis and the method on the vertical axis. Therefore all
simulation results for β = 0 and Ind are shown in this plot.
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Figure 22: MSE for Ind and β = 0
The median MSE decreases with the sample size from 0.200 (n = 25) over 0.099 (n = 50)
to 0.047 (n = 100). On the other hand it increases for the residual variance from 0.013
(σ2 = 1) over 0.090 (σ2 = 9) to 0.243 (σ2 = 25) and the random slope variance from
0.109 (σ2R = 0) over 0.113 (σ
2
R = 0.01) to 0.123 (σ
2
R = 0.4).
For σ2 = 1 summary has the highest MSE for 8 settings and the second highest for
(σ2 = 1;σ2R = 0.4;n = 25), where gee_uns has the highest MSE, which is among the
four models with the highest MSE for all 9 settings. Otherwise there is no clear trend
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observable and the MSE does not diﬀer much between the models. For example, for
(σ2 = 1;σ2R = 0;n = 25) summary has a MSE of 0.040 and for the other models it only
ranges between 0.0160 and 0.0156.
For σ2 = 9 and σ2 = 25 summary has the highest MSE for all 18 settings and the
remaining models do not diﬀer a lot.
Exchangeable correlation
For the simulated data with low exchangeable correlation structure for the repeated
measures, the mean MSE over all n, σ2 and σ2R is almost the same for β = 0 (0.153),
β = 0.5 (0.153) and β = 1 (0.153). Also, the diﬀerent characteristics of the models
are the same. Therefore only the results for β = 0 will be presented here. This also
holds for ExcMed and ExcHigh. The median MSE decreases with the magnitude of the
correlation from 0.048 (ExcLow) over 0.031 (ExcMed) to 0.015 (ExcHigh).
The median MSE decreases with the sample size from 0.109 (n = 25) over 0.055 (n = 50)
to 0.027 (n = 100). On the other hand it increases for the residual variance from 0.008
(σ2 = 1) over 0.049 (σ2 = 9) to 0.134 (σ2 = 25) and the random slope variance from
0.061 (σ2R = 0) over 0.061 (σ
2
R = 0.01) to 0.069 (σ
2
R = 0.4).
For ExcLow, gee_uns has a tremendous MSE for (σ2 = 1;σ2R = 0.4;n = 25) (21.218) and
(σ2 = 1;σ2R = 0.4;n = 50) (7.254) and the highest MSE for (σ
2 = 1;σ2R = 0.4;n = 100).
For the other 24 settings summary has the highest error. The remaining models have a
comparable MSE which never exceeds 0.250.
In case of ExcMed and ExcHigh the results are similar. For ExcMed, gee_uns has a
tremendous MSE for (σ2 = 1;σ2R = 0.4;n = 25) (23.308), (σ
2 = 1;σ2R = 0.4;n = 50)
(6.951) and (σ2 = 1;σ2R = 0.4;n = 100) (12.260). Again, summmary hast the highest
MSE for the remaining settings.
For ExcHigh, gee_uns has a tremendous MSE for (σ2 = 1; σ2R = 0.4;n = 25) (55.636)
and (σ2 = 1;σ2R = 0.4;n = 50) (141.848) and the highest MSE for (σ
2 = 1, 9;σ2R =
0, 0.01;n = 25), (σ2 = 1, σ2R = 0.4, n = 25, 50, 100) and (σ
2 = 25, σ2R = 0, 0.4, n = 25).
For the other 16 settings summary has the highest error. The remaining models have a
comparable MSE which never exceeds 0.200.
Auto-regressive correlation
For the simulated data with low auto-regressive correlation structure for the repeated
measures, the mean MSE over all n, σ2 and σ2R is almost the same for β = 0 (0.240),
β = 0.5 (0.240) and β = 1 (0.240). Also, the diﬀerent characteristics of the models are
the same. Therefore only the results for β = 0.5 will be presented here. This also holds
for ArMed and ArHigh.
The median MSE decreases with the sample size from 0.195 (n = 25) over 0.098 (n = 50)
to 0.050 (n = 100). On the other hand it increases for the residual variance from 0.013
(σ2 = 1) over 0.089 (σ2 = 9) to 0.241 (σ2 = 25) and the random slope variance from
0.111 (σ2R = 0) over 0.112 (σ
2
R = 0.01) to 0.120 (σ
2
R = 0.4).
For ArLow, gee_uns has a tremendous MSE for (σ2 = 1;σ2R = 0.4;n = 25) (35.957),
(σ2 = 1;σ2R = 0.4;n = 50) (4.363) and (σ
2 = 1;σ2R = 0.4;n = 100) (1.609). For the other
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24 settings summary has the highest error. The remaining models have a comparable
MSE which never exceeds 0.450.
In case of ArMed and ArHigh the results are similar. For ArMed, gee_uns has a tremen-
dous MSE for (σ2 = 1;σ2R = 0.4;n = 25) (11425.3), (σ
2 = 1;σ2R = 0.4;n = 50) (12.564),
(σ2 = 1;σ2R = 0.4;n = 100) (29.790), (σ
2 = 9;σ2R = 0.4;n = 25) (14.044) and (σ
2 =
25;σ2R = 0.01;n = 25) (2.073) and the highest error for (σ
2 = 1;σ2R = 0.01;n = 25),
(σ2 = 9;σ2R = 0.4;n = 50) and (σ
2 = 25;σ2R = 0.4;n = 50). Again, summmary has the
highest MSE for the remaining settings.
For ArHigh, gee_uns has a tremendous MSE for 11 and the highest MSE of all models
for 14 settings. For the remaining 2 settings summary has the highest error. The very
high errors for gee_uns occure in case of a low sample size and a high residual variance.
The remaining models have a comparable MSE which never exceeds 0.200.
Unstructured correlation
For the simulated data with unstructured correlation matrix for the repeated measures,
the median MSE over all n, σ2 and σ2R is the same for β = 0 (0.065), β = 0.5 (0.065) and
β = 1 (0.065). Also, the diﬀerent characteristics of the models are the same. Therefore
only the results for β = 1 will be presented here.
The median MSE decreases with the sample size from 0.114 (n = 25) over 0.055 (n = 50)
to 0.028 (n = 100). On the other hand it increases for the residual variance from 0.009
(σ2 = 1) over 0.051 (σ2 = 9) to 0.136 (σ2 = 25) and the random slope variance from
0.060 (σ2R = 0) over 0.063 (σ
2
R = 0.01) to 0.073 (σ
2
R = 0.4).
The model summary has the highest MSE for 21 of the 27 settings. For the remaining
6 settings, gee_uns has the highest error, whereas it has a tremendous MSE for (σ2 =
1;σ2R = 0.4;n = 25, 50, 100) (15.344, 12.526 and 80571.1) and (σ
2 = 9, 25;σ2R = 0;n =
25) (1.067 and 2.964).
For the remaining models the MSE does not diﬀer much between the models and it
never exceeds 0.300. For example, for (σ2 = 9;σ2R = 0;n = 50) summary has a MSE of
0.069 and for the other models it only ranges between 0.044 and 0.040.
3.5. Discussion
3.5.1. Summary measure SLANC
The summary statistic SLANC computes the slope of all post-baseline measurements for
each subject and computes an ANOCVA with these slopes as dependent variable and
the baseline measurements as a covariate afterwards.
If it is applied to the simulated data with independent correlation structure it shows the
lowest power for all 27 simulation settings. However, in some cases other methods show
a lower Type I Error.
In case of an exchangeable structure with low correlation, summary performs slightly
better but still has the lowest or second-lowest power for most scenarios. With medium
and high correlation the model performs even better and has the ﬁfth-lowest power in
case of no or a low random slope eﬀect and the third-lowest power in case of a high
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random slope eﬀect. Although summary has the lowest power for ExcLow, it only has
the ﬁfth-lowest Type I Error.
The same trend is observable for the auto-regressive correlation structure. The model
globally shows a low power compared to the remaining models, but performs slightly
better the higher the magnitude of the simulated correlation.
A main disadvantage of summary is that it does not account for the within subject
variance. The slope of a subject that has a perfect linear trend is accounted for with
the same weight as a subject with no clear observable trend and a high variance. The
repeated measurements of a subject deviate less from the linear trend the more they
depend on each other. That might explain why summary performs slightly better when
the magnitude of the correlation increases.
The main advantages of summary statistics are its simple application and interpretation
and the fact that it is not necessary to account for the dependency of the repeated
measures. However, the presented results show that other methods should be used to
analyse data of a randomized clinical trial with repeated measurements.
3.5.2. Repeated measures ANOVA
The rmANOVA has the second-lowest power for 24 and the third-lowest power for 3 of
all settings but has a Type I Error above the third quartile of all models in 7 settings
for the simulated data with independent correlation structure.
In case of an exchangeable structure 5 models perform worse than rmANOVA if there
is no or a low random slope eﬀect and 6 models if there is a high random slope eﬀect.
Again, the model is higher in the ranking listing the Type I Error. The same goes for
the unstructured correlation. If the data is simulated with an auto-regressive structure,
the performance improves with the magnitude of the correlation.
Repeated measures ANOVA accounts for the dependency between the repeated measure-
ments by assuming compound symmetry. That explains why it performs better with an
exchangeable structure than with an independent structure. Also, the auto-regressive
structure converges to compound symmetry with increasing correlation level.
In summary, rmANOVA has a low power in most scenarios and a high Type I Error at
the same time.
3.5.3. Generalized Estimating Equations
In general, the four GEE models perform poorly in case of a high random slope variance
and a low residual variance but they improve compared to the other models if the residual
variance increases. This leads to the conclusion that GEE models cannot handle data
very well if a big part of the variability in the data can be ascribed to random eﬀects.
In case of an independent correlation structure and no or a low random slope eﬀect, the
GEE models perform very well whereas gee_uns shows the highest power but also the
highest Type I Error. In addition, a slight caveat must be entered here because gee_uns
often has a tremendous MSE and therefore should be dealt with carefully. Even with a
high random slope eﬀect, the GEE models perform comparably well. Consequently, the
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GEE models are a good choice in the unlikely case of independent repeated measures.
If the data is simulated with an exchangeable correlation structure gee_exc and gee_ind
have the third and forth-highest power but a Type I Error below the median of all models
if there is a high random slope eﬀect. Therefore they can be considered the best models
in this scenario. The same holds if there is no or a low random slope eﬀect because
gee_exc and gee_ind are among the three models with the highest power for all three
levels of correlation and have a competitive Type I Error.
If the data follows an auto-regressive correlation structure, the GEE models have a power
below the median if there is a high random slope eﬀect. In case of no or a low random
slope eﬀect, gee_ar has the third-highest power for ArMed and forth-highest power for
ArLow and ArHigh. The model gee_uns is among the ﬁve best models if there is a low
or medium correlation level but has the forth-lowest power for ArHigh.
In case of an unstructured correlation between the repeated measures, the linear mixed
models perform better than the GEE models.
3.5.4. Linear Mixed Models
In case of an independent correlation structure, the GEE models usually perform better
than the linear mixed models. Only in the case of a high random slope eﬀect and a
low residual variance or a medium residual variance and a high sample size, the linear
mixed models perform better but also have a high Type I Error, especially lmm_exc,
lmm_ar_rand and lmm_ind_rand.
When the data is simulated with an exchangeable correlation structure lmm_exc and
lmm_uns have the highest power if there is a high random slope eﬀect but also the
highest Type I Error. The models gee_exc and gee_ind have the third and forth-highest
power and a comparably low Type I Error and therefore can be considered a better choice
in this scenario. Surprisingly, lmm_exc, lmm_uns and lmm_ar perform better than the
corresponding methods assuming a random slope eﬀect although a high random slope
eﬀect was simulated. In case of no or a low random slope eﬀect, the GEE models perform
best followed by lmm_uns, lmm_uns_rand, lmm_exc and lmm_exc_rand. The linear
mixed models assuming an auto-regressive or independent correlation structure perform
poorly if an exchangeable sturcture is simulated.
If the data follows a low auto-regressive correlation structure, lmm_exc, lmm_exc_rand
and lmm_ind_rand have the highest power over all settings. If there is no or a low
random slope eﬀect lmm_ar and lmm_ar_rand are among the four models with the
lowest power but in case of a high random slope eﬀect they have the highest power
after the three afore mentioned linear mixed models. With a higher level of simulated
correlation, lmm_ind_rand no longer performs well but lmm_exc and lmm_exc_rand
still have the highest power.
In case of an unstructured correlation between the repeated measures, the linear mixed
models with the assumption of an exchangeable or unstructured correlation perform best
and the linear mixed models with the assumption of an independent or auto-regressive
correlation perform poorly.
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3.5.5. Conclusion
The methods summary and rmANOVA should not be used for analysing the data of
a randomized clinical trial with repeated measurements because they perform poorly
compared to generalized estimating equations and linear mixed models.
It is very unlikely that the repeated measures within one subject in a clinical trial are
independent. Compound symmetry or exchangeable correlation structure might be a
reasonable assumption in some cases but still doubtful if there is a long time interval
between the repeated measures. In these scenarios gee_uns respectively gee_exc and
gee_ind can be recommended.
As shown by the real data of clinical trials that was collected and described in chapter
3.2.2, auto-regressive correlation structure and unstructured correlation are the closest
to the real world among all simulated correlation structures.
If the data follows an auto-regressive correlation structure, the linear mixed models
assuming an exchangeable structure are the best. Surprisingly, the linear mixed model
assuming an auto-regressive structure can only be recommended if there is a high random
slope eﬀect, i.e. the subjects respond to the treatment with diﬀerent intensity. Of course,
this is an appropriate assumption in a clinical trial.
In case of the unstructured correlation matrix (14), the linear mixed models assuming
an exchangeable structured or unstructured correlation perform best.
In general, the power increases with increasing sample size and decreases with increasing
residual variance and random slope variance, whereas the Type I Error decreases with
increasing sample size and increasing residual variance and increases with increasing
random slope variance. The coverage of the 95% conﬁdence interval increases with the
sample size and decreases with the random slope variance. Usually, models with a high
power have a low coverage and vice versa. The MSE decrease with the sample size and
increases with the variances.
3.5.6. Challenges and Limitations
For this simulation study, only a linear treatment eﬀect was considered. That means that
the results of this work only apply if there is a linearly increasing divergence between
treatment arms over time. Although this kind of eﬀect is common in clinical trials with
repeated measurements [1], other eﬀects can occur. An example is a quick treatment
response which occurs at the ﬁrst post-baseline measurement and remains steady for the
following measurements [7].
Another aspect that is not considered in this study is missing data although almost all
randomized clinical trials have at least a few missing observations [72]. This can also be
seen in table 4 which lists the amount of missing data in the RCTs from the literature
review. A systematic review [73] showed that half of all trials with repeated measure-
ments have missing observations for even more than 10% of the subjects. Therefore, it
is an important aspect that should be considered in an enhancement of this simulation
study. Some statistical methods can deal with missing data, for others it is necessary to
apply imputation methods or omit subjects with missing observations. Mishandling the
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occurrence of missing data can lead to substantial bias. More information on imputing
missing data can be found in [74, 75, 76, 77].
As most of the trials from the literature review described in chapter 3.2.1 had a quan-
titative primary outcome, this was the scenario that was chosen for this simulation
study. However, qualitative outcomes are also common in medicine and a simulation
study comparing statistical methods analysing repeated measurements of a qualitative
primary outcome might be desirable.
3.5.7. Quality of reports of RCTs
To improve the quality of reporting parallel group randomized trials the CONSORT
statement [32] provides several guidelines including the request to report the estimated
eﬀect size and its precision for each primary and secondary outcome. As described in
the discussion of Part I in chapter 2.4 this statement is not always fulﬁlled in the papers
recovered for the meta-analysis.
From the 28 papers recovered for the literature review guiding the simulation parameters,
7 (25.0%) did not report eﬀect size and its precision for each time and 3 (10.7%) did
report eﬀect size but not its precision.
In order to estimate the correlation matrix of the repeated measurements of randomized
clinical trial the change variability between all times at which measurements are taken
must be reported. However, with an increasing number of repeated measurements that
would require the reporting of a large number of values and might get confusing. That
might be the reason why none of the 28 papers provided suﬃcient information to estimate
the correlation matrix.
However, it would be desirable that reporters at least give some information on the
correlation structure they expected before conducting the trial or estimated from the
data. Even in the reports of the studies that used a linear mixed model or generalized
estimating equations as an analysis method, the assumed correlation structure is not
even mentioned.
Another possibility to estimate the correlation matrix of an outcome of a clinical trial is
to obtain the original data. The beneﬁts of publishing the data of a trial was discussed
[49, 50, 51] but it is still uncommon in practice [52, 53, 54]. Therefore data of only four
trials could be collected.
3.5.8. Previous work
Omar et al. [78] compare summary statistics, repeated measures ANOVA, mixed models
and GEE and come to the conclusion that mixed models and GEE are superior to
the more routinely used summary statistics and repeated measures ANOVA. However,
this comparison is based on only one real data set. Nevertheless, this result could be
conﬁrmed by this simulation study. Twisk [79] and Gardiner et al. [80] also compared
methods for the analysis of longitudinal data of a clinical trial based on one real data
set only.
Chu et al. [81] conducted a simulation study to compare various methods, including
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mixed modeling and GEE, for multicentre trials. Their main goal was to investigate the
best way to avoid biased estimates of the treatment eﬀect due to the diﬀerent centres.
They advise to include centre as a random intercept in the statistical model.
Lu et al. [82] conducted a simulation study comparing LMM, weighted generalized
estimating equations (WGEE) and augmented WGEE (AWGEE) in the case of missing
data and skewed non-normal data. The simulation studies by Chu et al. and Wu et al.
consider diﬀerent data scenarios as this simulation study.
Ma et al. [83] conducted a simulation study to compare rmANOVA, GEE and LMM
with varying sample sizes, varying number of repeated measures and scenarios with and
without missing data. They come to the conclusion, that GEE and LMM achieve higher
power than rmANOVA and suggest to use LMM if there are subject-speciﬁc eﬀects and
GEE otherwise. However, they do not even mention dependency between the repeated
measures and therefore it is unclear if it was considered in their simulation study.
To my knowledge, there is no noteworthy work except for the aforementioned that
investigates the performance of statistical methods for randomized clinical trials with
repeated measurements and a quantitative outcome. Also, there is no simulation study
that considers as many scenarios as this one.
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A. Appendix Part I
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Figure 23: Directory structure of the project
Figure 23 shows the directory structure of the project. The folder Part I contains all
the data for the meta-analysis described in chapter 2.
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The folders 2010 papers and 2013 papers contain the papers that were found with the
systematic literature review from 2010 and 2013. They are organized in subfolders in
excluded and included papers. Additionally, there is a pdf -ﬁle in each folder which con-
tains the abstracts of all the papers that were retrieved.
The folder Data contains the Excel -ﬁles with all the data that was retrieved from the
papers and the folder r_scripts contains the scripts that are analyzing this data as de-
scribed in chapter 2.2. The ﬁle paper_ﬂow.pptx contains ﬁgure 2.
The folder Part II contains all the ﬁles concerning the simulation study described in
chapter 3.
The folder literature_review contains all the information for the literature review de-
scribed in chapter 3.2.1. The subfolder correlation contains the papers and data of the
studies original data could be collected from and the script correlation.R which calcu-
lates the correlation matrices of these studies.
The subfolder papers contains the papers data was retrieved from whose references are
listed in appendix B.1 and plots contains the ﬁgures which show the eﬀect over time for
these studies.
The ﬁle literature_review.xls contains the data that was retrieved, literature_review.R
is the code for the descriptive analysis of this data, paper_ﬂow.pptx contains ﬁgure 5
and search_strategy contains the search strategy that was used as a txt-ﬁle.
The folder simulation contains all the code and results of the simulation study. The sub-
folder r_scripts contains the project ﬁle simulation.Rproj and various functions. The
functions summaryStatistics.R, rmAOV.R, lmm.R and geeMarg.R are used to apply the
statistical models to the data. The ﬁle dataFramework.R creates the framework of the
data with the columns subject, time and treatment in long format and the function
dataSimulate.R takes this framework and adds the simulated data. The ﬁle simu.R
uses all these afore mentioned functions to simulate the data, apply the methods on the
data and return the results. Based on these results, the function createPerformance.R
calculates the performance measures by means of the support function performance.R.
With the ﬁle results.R, it is possible to take a close look at the results with the support
functions standings.R which provides a descriptive analysis, createPlots.R which creates
the plots that are also shown in chapter 3.4 and dynamicalPlot.R. The function dynam-
icalPlot.R creates the same plots as createPlots.R with the additional feature that it
allows interactive working within RStudio by changing the controls eﬀect size and cor-
relation structure. The function results_linear_model.R contains the code to compute
the linear regression models that were applied on the simulation results.
Due to the high computational cost, all simulations were run on the simulation servers
of the Department of Statistics at the Ludwig-Maximilians-University Munich. The
subfolder server_scripts contains all the scripts that were run on the server and the
corresponding Rout-ﬁles containing the output.
The subfolder results contains all the results. The raw simulation results in the folder
RData, the performance measures in the folder performance and the plots in the folder
plots.
Additionally, this thesis and this electronic appendix named README.pdf are saved in
the root directory.
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